Details of the Drug

General Information of Drug (ID: DM15F0X)

Drug Name
Gefitinib
Synonyms
Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
Indication
Disease Entry ICD 11 Status REF
Colon adenocarcinoma N.A. Approved [1]
Glioblastoma 2A00 Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Rectal adenocarcinoma 2B92 Approved [1]
Rectum mucinous adenocarcinoma N.A. Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Head and neck cancer 2D42 Phase 3 [2]
Urethral cancer 2C93 Phase 2 [2]
Colon cancer 2B90.Z Investigative [1]
Colon mucinous adenocarcinoma N.A. Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01EB01: Gefitinib
L01EB: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 446.9
Logarithm of the Partition Coefficient (xlogp) 4.1
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
60% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The clearance of drug is 595 mL/min []
Elimination
2% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 48 hours [5]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.089% [5]
Vd
The volume of distribution (Vd) of drug is 1400 L []
Water Solubility
The ability of drug to dissolve in water is measured as 0.0017 mg/mL [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Diarrhea rs2231142 ABCG2 OTW8V2V1 [7]
Chemical Identifiers
Formula
C22H24ClFN4O3
IUPAC Name
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
Canonical SMILES
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
InChI
InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InChIKey
XGALLCVXEZPNRQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
123631
ChEBI ID
CHEBI:49668
CAS Number
184475-35-2
UNII
S65743JHBS
DrugBank ID
DB00317
TTD ID
D09XZB
VARIDT ID
DR00423
INTEDE ID
DR0764
ACDINA ID
D00299
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [10]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [13]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [12]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Gene/Protein Processing [14]
Adenosine receptor A1 (ADORA1) OTI7X39E AA1R_HUMAN Gene/Protein Processing [14]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Protein Interaction/Cellular Processes [15]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Drug Response [16]
Aurora kinase A (AURKA) OTMX0HYT AURKA_HUMAN Drug Response [17]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Gene/Protein Processing [18]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Gene/Protein Processing [19]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Drug Response [20]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [21]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Drug Response [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Colon adenocarcinoma
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Epidermal growth factor receptor (EGFR) DTT EGFR 1.04E-65 -0.89 -1.53
P-glycoprotein 1 (ABCB1) DTP P-GP 3.61E-73 -1.15E+00 -1.66E+00
Breast cancer resistance protein (ABCG2) DTP BCRP 1.46E-65 -1.41E+00 -1.41E+00
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 4.86E-01 -5.39E-02 -2.84E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 9.12E-01 9.67E-03 3.43E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 2.56E-19 -3.06E-01 -6.18E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 6.51E-02 -2.38E-02 -9.58E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.87E-03 -6.67E-02 -2.12E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1; GDSC2 3.0661 4.9942 0.3511 0.7959
EW-12 GDSC2 2.0738 4.5888 0.002 3.7931
TC-71 GDSC1; GDSC2 2.1215 3.941 0.3255 1.9014
SK-N-MC CTRP2 2.2106 2.8327 2.2106 25.5414
ES8 GDSC1; GDSC2 2.279 4.8177 0.0224 3.2993
U-CH2 GDSC2 2.5086 5.0288 0.0605 2.7362
NOS-1 [Human HNSCC] GDSC1; GDSC2 2.5319 5.121 0.0327 2.8389
EW-16 GDSC1; GDSC2 2.706 7.356 -0.8935 7.7299
ES4 GDSC1; GDSC2 2.706 8.1912 -1.2923 9.9752
SK-ES-1 GDSC1; GDSC2; CTRP2 2.7169 4.9943 2.6365 22.3903
CAL-72 GDSC1; GDSC2 2.7573 10.0341 -2.1495 14.3836
ES5 GDSC1; GDSC2 2.7779 5.8952 -0.1728 3.561
ES6 GDSC1; GDSC2 2.8952 6.0516 -0.1759 3.3995
EW-1 GDSC1; GDSC2 2.9085 8.1654 -1.1443 8.7315
ES1 GDSC1; GDSC2 2.9548 4.691 0.4196 0.6394
EW-24 GDSC1; GDSC2 2.9946 4.264 0.5905 0.1801
MHH-ES-1 GDSC1; GDSC2; CTRP2 3.0762 4.6885 3.0509 19.8144
SK-PN-DW GDSC1; GDSC2 3.0853 7.4015 -0.675 5.7942
EW-7 GDSC1; GDSC2 3.1386 16.0157 -4.8086 23.9433
CHSA0011 GDSC1; GDSC2 3.1552 6.4446 -0.2054 3.18
CADO-ES1 GDSC1; GDSC2 3.2027 5.0864 0.3735 0.6327
NY GDSC1; GDSC2 3.4383 7.9014 -0.6928 5.3016
EW-18 GDSC1; GDSC2 3.4555 11.1668 -2.2112 13.1592
Hs 888.T CTRP2 3.4916 5.9938 3.2722 17.773
EW-22 GDSC1; GDSC2 3.5352 5.685 0.2858 0.707
CHSA8926 GDSC1; GDSC2 3.6151 5.3658 0.4329 0.2938
SJSA-1 GDSC1; GDSC2; CTRP2 3.6172 5.32 3.5524 16.3536
CHSA0108 GDSC1; GDSC2 3.7114 6.07 0.2139 0.8259
ES7 GDSC1; GDSC2 3.7438 6.4105 0.0971 1.2034
SW1353 CTRP2 3.8054 5.0401 3.7849 14.9853
HuO-3N1 GDSC1; GDSC2 3.967 15.1134 -3.763 18.6753
A-673 GDSC1; GDSC2; CTRP2 4.1299 5.3248 4.0986 12.8312
CAL-78 GDSC1; GDSC2; CTRP2 4.1359 6.1348 3.9363 13.3855
H-EMC-SS GDSC1; GDSC2 4.3065 6.7148 0.2137 0.5239
MG-63 GDSC1; GDSC2; CTRP2 4.3321 5.7508 4.2469 11.674
EW-3 GDSC1; GDSC2 4.3429 15.8574 -3.861 18.2767
EW-11 GDSC1; GDSC2 4.3749 11.6084 -1.825 9.5306
HuO9 GDSC1; GDSC2 4.5236 6.5335 0.3563 0.1922
SaOS-2 GDSC1; GDSC2; CTRP2 4.8317 8.6417 3.6351 12.7065
G-292 clone A141B1 GDSC1; GDSC2; CTRP2 4.9679 7.6476 4.2326 9.962
U2OS GDSC1; GDSC2; CTRP2 5.0453 9.0433 3.6483 12.1488
TC71 CTRP2 5.1886 7.0465 4.7266 7.4481
Hs 822.T CTRP2 5.1997 6.2634 5.0546 6.147
EW-13 GDSC1; GDSC2 5.2853 23.2343 -6.7797 24.8707
HOS GDSC1; GDSC2; CTRP2 5.3423 7.9653 4.4505 8.172
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 214 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 2.2652 5.4011 2.0762 25.8243
MEC1 CTRP2 4.2623 6.0063 4.1098 12.4047
JM1 GDSC1; GDSC2; CTRP2 4.4342 5.605 4.3847 10.8711
EoL-1 GDSC1; GDSC2; CTRP2 -0.384 1.7242 -0.3863 42.7363
KG-1 GDSC1; GDSC2 0.3472 39.5639 -18.8286 43.9796
DB GDSC1; GDSC2; CTRP2 0.8478 9.3842 -0.7916 38.5905
Sc-1 GDSC1 1.1295 2.8167 -1.5558 0.5815
RPMI-8866 GDSC1 1.1985 17.2389 -8.3583 30.3741
SU-DHL-5 GDSC1; GDSC2 1.3332 3.2664 0.1311 4.5894
ALL-PO GDSC1; GDSC2 1.3592 9.6228 -3.0159 21.9951
Pfeiffer CTRP2 1.4022 2.4292 1.4022 30.9269
MV4-11 GDSC1; GDSC2; CTRP2 1.4583 4.8903 1.3007 31.0079
NU-DUL-1 GDSC1; GDSC2; CTRP2 1.5151 3.4544 1.4243 20.011
MOLM-13 GDSC1; GDSC2; CTRP2 1.8093 4.8412 1.6867 28.5635
NCO2 CTRP2 1.8571 4.0131 1.8299 27.9875
MY-M12 GDSC1; GDSC2 1.8609 4.5923 -0.1392 5.0407
GA-10 GDSC1; GDSC2; CTRP2 1.9617 2.8294 1.9616 27.1379
NKM-1 GDSC1; GDSC2 1.9832 31.1886 -13.283 39.0553
697 GDSC1; GDSC2; CTRP2 1.9951 2.7555 1.9951 26.9158
EB2 GDSC1; GDSC2 2.0741 4.8076 -0.1004 4.3762
Hs 445 GDSC2 2.2116 4.3055 0.2144 2.3642
BL-41 GDSC1; GDSC2 2.233 3.6799 0.4948 0.9418
Loucy GDSC1; GDSC2 2.2643 4.3246 0.2356 2.1648
RC-K8 GDSC1; GDSC2 2.2794 3.9083 0.4229 1.2147
Farage GDSC1; GDSC2 2.3158 8.7113 -1.8216 13.7435
DoHH2 GDSC1; GDSC2 2.3603 17.9157 -6.3527 29.6326
LP-1 GDSC1; GDSC2; CTRP2 2.3854 3.394 2.3851 24.3224
Karpas-45 GDSC1; GDSC2 2.4259 10.3938 -2.568 17.1823
KMS-20 CTRP2 2.429 3.8248 2.4247 24.1005
MOLT-13 GDSC1; GDSC2 2.4336 18.6436 -6.6574 30.1138
JURL-MK1 GDSC1; CTRP2 2.4376 4.652 2.3828 24.1588
KMS-34 CTRP2 2.4412 3.2819 2.4411 24.0054
Karpas-231 GDSC1; GDSC2 2.4476 4.2492 0.3644 1.2949
DND-41 GDSC1; GDSC2 2.4505 4.5297 0.2471 1.8501
A4/Fukuda GDSC1; GDSC2; CTRP2 2.4524 3.1272 2.4524 23.8757
SUP-B8 GDSC1; GDSC2 2.4877 4.7289 0.1808 2.1327
CESS GDSC1; GDSC2 2.4905 4.5663 0.2523 1.7732
RPMI-8402 GDSC1; GDSC2; CTRP2 2.5228 3.7942 2.5202 23.4168
Mono-Mac-6 GDSC1; GDSC2; CTRP2 2.5358 9.3189 1.0051 28.5498
OPM-2 GDSC1; GDSC2 2.5367 4.354 0.3646 1.1991
ML-2 GDSC1; GDSC2 2.5368 11.7069 -3.1328 19.397
Ku812 GDSC1; GDSC2; CTRP2 2.5395 3.9391 2.5343 23.3143
K-562 GDSC1; GDSC2; CTRP2 2.5469 3.7342 2.5453 23.253
MHH-CALL-2 GDSC1; GDSC2 2.5523 4.3993 0.3535 1.2315
IM-9 GDSC1; GDSC2 2.5652 3.8324 0.5814 0.3701
Daudi GDSC1; GDSC2; CTRP2 2.5916 3.1448 2.5916 22.9506
A3/Kawakami GDSC1; GDSC2; CTRP2 2.5947 3.5877 2.5943 22.9315
MOLT-4 GDSC1; GDSC2 2.6113 8.037 -1.283 10.128
OCI-Ly7 GDSC1; GDSC2 2.6192 4.2548 0.4429 0.8008
Karpas-299 GDSC1; GDSC2; CTRP2 2.6233 3.6205 2.6228 22.7414
SKM-1 GDSC1; GDSC2; CTRP2 2.6282 4.2688 2.6129 22.7586
SU-DHL-16 GDSC1; GDSC2 2.6315 3.9698 0.5573 0.4044
L-540 GDSC1; GDSC2; CTRP2 2.6333 3.9675 2.6289 22.6881
KMS-12-BM GDSC1; GDSC2; CTRP2 2.6696 3.9185 2.6666 22.442
Peer CTRP2 2.674 4.0659 2.6679 22.4745
SEM CTRP2 2.6761 4.1946 2.6657 22.4748
MOLT-3 CTRP2 2.677 3.2804 2.6769 22.4344
SUP-T1 GDSC1; GDSC2; CTRP2 2.6851 3.7469 2.6842 22.3322
CML-T1 GDSC1; GDSC2; CTRP2 2.6951 3.7427 2.6943 22.2655
SUP-T11 CTRP2 2.6988 4.6835 2.6553 22.4353
KMS-11 GDSC1; GDSC2; CTRP2 2.6992 4.4513 2.6755 22.3147
ARH-77 GDSC1; GDSC2 2.7126 6.6456 -0.5552 5.7928
SU-DHL-10 GDSC2; CTRP2 2.7174 3.2692 2.7174 22.1647
Mono-Mac-1 CTRP2 2.7266 5.3534 2.5861 22.585
ST486 GDSC1; GDSC2 2.7292 4.4279 0.4239 0.7847
Hs 611.T CTRP2 2.7403 5.0337 2.6557 22.2997
ME1 GDSC1; GDSC2 2.743 3.9169 0.6195 0.2008
Ri-1 CTRP2 2.7525 4.53 2.7253 22.0223
Karpas-620 GDSC1; GDSC2 2.7657 4.1681 0.5378 0.3893
P32/ISH GDSC1; GDSC2 2.7757 4.4892 0.4205 0.7615
KMS-21-BM CTRP2 2.7891 4.01 2.7859 21.698
CTV-1 GDSC1; GDSC2 2.8084 17.3251 -5.7088 27.1433
Jurkat GDSC1; GDSC2; CTRP2 2.8428 3.7592 2.8424 21.2821
JVM-3 GDSC1; GDSC2; CTRP2 2.8617 11.3913 0.4091 29.3855
Kasumi-2 CTRP2 2.8626 5.5394 2.6957 21.7719
MOLT-16 GDSC1; GDSC2; CTRP2 2.8676 4.1408 2.8628 21.1318
AML-193 CTRP2 2.874 4.3282 2.8631 21.158
SCC-3 GDSC2 2.8755 4.2196 0.5619 0.2797
HC-1 GDSC1; GDSC2 2.8782 5.53 0.0424 2.3093
NU-DHL-1 CTRP2 2.8843 4.2027 2.8781 21.0739
HDLM-2 GDSC1; GDSC2; CTRP2 2.8913 5.4262 2.7502 21.4417
JJN-3 GDSC1; GDSC2; CTRP2 2.8939 4.4196 2.8792 20.9905
RS4;11 GDSC1; GDSC2; CTRP2 2.8975 4.8851 2.8434 21.0999
LAMA-84 GDSC1; GDSC2; CTRP2 2.9047 4.1863 2.8994 20.8871
NALM-6 GDSC1; GDSC2; CTRP2 2.907 4.1698 2.9021 20.8704
RPMI-8226 GDSC1; GDSC2; CTRP2 2.9159 3.8768 2.9152 20.7973
PF-382 GDSC1; GDSC2; CTRP2 2.9201 4.6223 2.8931 20.8579
KMS-26 CTRP2 2.9214 3.8205 2.921 20.807
TALL-1 [Human adult T-ALL] GDSC2; CTRP2 2.9231 5.3413 2.8011 21.2121
Karpas-1106P GDSC1; GDSC2 2.9546 4.4038 0.526 0.3321
TUR GDSC1; GDSC2 2.9563 8.4101 -1.229 9.1029
P30/OHK GDSC1; GDSC2 2.9635 4.9538 0.3217 0.9815
P31/FUJ GDSC1; GDSC2; CTRP2 2.9725 4.8541 2.9264 20.574
TK [Human B-cell lymphoma] GDSC1; GDSC2 2.9774 4.6217 0.4551 0.5147
ALL-SIL GDSC1; GDSC2 2.9807 4.7616 0.4037 0.6749
OCI-AML-2 GDSC1; GDSC2; CTRP2 2.9957 4.1047 2.9933 20.2729
Reh GDSC1; GDSC2; CTRP2 3.0008 4.0409 2.9993 20.2358
KM-H2 GDSC1; GDSC2; CTRP2 3.0087 4.2018 3.0047 20.1914
QIMR-WIL GDSC1; GDSC2 3.0169 11.7337 -2.7929 16.8085
MN-60 GDSC1; GDSC2 3.0254 8.0252 -1.0022 7.7132
L-363 GDSC1; GDSC2; CTRP2 3.0275 4.4512 3.0153 20.0943
PL21 CTRP2 3.0384 4.3796 3.0296 20.0561
Ki-JK CTRP2 3.0476 4.3776 3.039 19.9938
KE-97 CTRP2 3.0611 4.5944 3.042 19.9393
KE-37 GDSC1; GDSC2; CTRP2 3.062 4.249 3.0577 19.8381
WSU-DLCL2 GDSC1; GDSC2; CTRP2 3.0628 3.9763 3.0621 19.8209
MOLM-6 CTRP2 3.0689 6.9114 2.525 21.7631
P12-Ichikawa GDSC1; GDSC2; CTRP2 3.0872 4.3802 3.0795 19.6819
VL51 GDSC1; GDSC2 3.1327 4.9232 0.4059 0.5743
WIL2 NS GDSC1; GDSC2 3.1755 4.714 0.4992 0.3065
NB4 GDSC1; GDSC2; CTRP2 3.1797 4.1938 3.1779 19.0475
L-1236 GDSC1; GDSC2 3.1808 5.969 0.0114 2.0922
SU-DHL-1 GDSC2; CTRP2 3.1881 4.0072 3.1877 19.0304
BALL-1 GDSC1; GDSC2 3.1908 5.224 0.3163 0.8287
CRO-AP2 GDSC1; GDSC2 3.2068 5.0451 0.3906 0.5781
NK-92MI GDSC2 3.2267 4.539 0.5789 0.1424
SR GDSC1; GDSC2; CTRP2 3.2432 4.4041 3.2379 18.6372
JSC-1 GDSC1; GDSC2 3.2473 5.5911 0.1976 1.2243
PL-21 GDSC1; GDSC2 3.2607 5.7686 0.1327 1.4751
LC4-1 GDSC1; GDSC2 3.2614 5.395 0.2807 0.9026
HT GDSC1; GDSC2; CTRP2 3.2697 3.9798 3.2696 18.4436
MHH-PREB-1 GDSC1; GDSC2 3.2838 5.0516 0.4191 0.4575
BC-3 GDSC2 3.2963 4.8267 0.5044 0.254
NCI-H929 GDSC1; GDSC2; CTRP2 3.298 4.2482 3.2965 18.2605
HEL GDSC1; GDSC2; CTRP2 3.3364 4.8078 3.3133 18.0775
JVM-2 GDSC1; GDSC2 3.3411 14.2637 -3.7964 20.1292
KYO-1 CTRP2 3.353 5.1837 3.2896 18.1456
F-36P CTRP2 3.3594 5.9628 3.136 18.6669
BV-173 GDSC1; GDSC2; CTRP2 3.3663 5.6438 3.2205 18.3027
BC-1 GDSC1; GDSC2 3.373 5.3085 0.3601 0.5763
RCH-ACV GDSC1; GDSC2; CTRP2 3.3909 5.3392 3.3061 17.9263
EM-2 GDSC1; GDSC2; CTRP2 3.3945 5.0638 3.3494 17.7657
KCL-22 GDSC1; GDSC2; CTRP2 3.3959 4.8272 3.3739 17.6785
DEL GDSC1; GDSC2; CTRP2 3.4025 3.9049 3.4025 17.5609
NOMO-1 GDSC1; GDSC2 3.407 4.8978 0.52 0.1926
CTB-1 GDSC1; GDSC2 3.4202 6.1408 0.0571 1.6393
L-428 GDSC1; GDSC2; CTRP2 3.4236 5.5766 3.297 17.8547
Ramos.2G6.4C10 GDSC1; GDSC2 3.4258 16.4384 -4.8026 23.3011
ATN-1 GDSC1; GDSC2 3.432 4.8155 0.557 0.131
ROS-50 GDSC1; GDSC2 3.481 5.5133 0.3278 0.612
CCRF-CEM GDSC1; GDSC2 3.5318 5.3092 0.4218 0.3462
KHM-1B CTRP2 3.5375 4.8286 3.5213 16.7557
M-07e CTRP2 3.5497 5.1161 3.5079 16.7614
WSU-NHL GDSC1; GDSC2 3.5634 5.2534 0.4533 0.2698
KOPN-8 GDSC1; GDSC2 3.577 5.2586 0.4564 0.2595
VAL GDSC1; GDSC2 3.5895 5.6323 0.3273 0.5567
MEG-01 GDSC1; GDSC2 3.6069 12.731 -2.8607 15.8137
BONNA-12 GDSC2 3.6483 6.1892 0.1413 1.1191
U-698-M GDSC1; GDSC2 3.67 6.2926 0.1106 1.2107
EHEB GDSC1; CTRP2 3.6968 5.1111 3.6641 15.7142
Jiyoye GDSC1; GDSC2 3.6986 6.8775 -0.1108 2.0809
Raji GDSC1; GDSC2; CTRP2 3.7228 5.1056 3.6921 15.5348
YT GDSC1; GDSC2 3.746 10.4748 -1.6911 10.0037
MOTN-1 CTRP2 3.7929 5.2639 3.7481 15.1517
SU-DHL-8 GDSC2; CTRP2 3.8072 5.8078 3.6631 15.4036
HH [Human lymphoma] GDSC1; GDSC2 3.8633 6.38 0.16 0.9036
THP-1 GDSC1; GDSC2; CTRP2 3.8764 5.7916 3.7423 14.8734
MLMA GDSC1; GDSC2 3.8812 9.1652 -1.0048 6.2289
DG-75 GDSC1; GDSC2 3.9168 6.0121 0.3169 0.4376
SET-2 CTRP2 3.9202 5.3406 3.8736 14.3095
SU-DHL-6 GDSC1; GDSC2; CTRP2 3.9267 6.3551 3.6415 15.0853
KMS-18 CTRP2 3.9611 5.4106 3.9073 14.0621
SK-MM-2 GDSC1; GDSC2; CTRP2 4.0168 5.2935 3.9824 13.5933
U266B1 GDSC1; GDSC2; CTRP2 4.0319 6.1236 3.8259 14.0987
MM1.S GDSC1; GDSC2; CTRP2 4.0374 5.751 3.9267 13.7216
U-937 CTRP2 4.1136 5.4741 4.0611 13.0415
MHH-CALL-4 GDSC2; CTRP2 4.2428 6.5683 3.9139 13.183
OCI-Ly19 GDSC1; GDSC2; CTRP2 4.2655 6.6588 3.9064 13.1157
KMS-27 CTRP2 4.2917 5.3357 4.2685 11.755
JeKo-1 GDSC1; GDSC2; CTRP2 4.2967 5.5785 4.2411 11.8063
SUP-M2 GDSC1; GDSC2; CTRP2 4.3206 4.9573 4.3191 11.463
CA46 GDSC1; GDSC2; CTRP2 4.3257 6.0733 4.1608 12.0006
KMOE-2 GDSC1; GDSC2 4.3747 14.9194 -3.3878 16.4293
RL GDSC1; GDSC2; CTRP2 4.3799 4.9152 4.3794 11.0653
SUP-HD1 GDSC1; GDSC2; CTRP2 4.4027 6.4235 4.1366 11.8604
GDM-1 GDSC1; GDSC2; CTRP2 4.4133 6.8547 3.9922 12.373
KY821 GDSC1; GDSC2 4.4246 16.3763 -4.055 18.8069
HuT 78 CTRP2 4.5248 6.8898 4.0974 11.6878
P3HR-1 CTRP2 4.5592 6.7153 4.2012 11.1955
Karpas-422 GDSC1; GDSC2; CTRP2 4.5595 6.1909 4.3816 10.4965
Granta-519 GDSC1; GDSC2; CTRP2 4.572 6.4718 4.3034 10.7489
MHH-CALL-3 CTRP2 4.598 7.5399 3.9041 12.2433
MOLP-2 CTRP2 4.6027 7.0822 4.1028 11.4529
Namalwa GDSC1; GDSC2; CTRP2 4.6042 6.1336 4.4474 10.1236
HPB-ALL CTRP2 4.6166 6.4924 4.3444 10.491
RPMI-6666 GDSC1; GDSC2; CTRP2 4.635 7.7663 3.8425 12.363
MOLP-8 GDSC1; GDSC2; CTRP2 4.6745 5.7821 4.612 9.3197
TF-1 CTRP2 4.6925 6.0515 4.5671 9.4456
OCI-AML-3 GDSC1; GDSC2; CTRP2 4.7101 5.749 4.6569 9.0508
HD-MY-Z CTRP2 4.7211 5.593 4.6938 8.9085
BE-13 GDSC1; GDSC2 4.7475 26.6279 -8.8406 29.7036
KO52 CTRP2 4.7873 6.0956 4.6582 8.8282
OCI-Ly3 CTRP2 4.8515 6.4992 4.5952 8.8736
EJM GDSC1; GDSC2; CTRP2 4.8664 6.8896 4.459 9.3328
Ci-1 CTRP2 4.9396 6.3841 4.7314 8.1083
HAL-01 GDSC1; GDSC2 4.9709 19.7453 -5.305 21.7105
ME1 CTRP2 5.021 6.4056 4.8116 7.573
SUP-B15 GDSC1; GDSC2; CTRP2 5.0677 6.4719 4.8374 7.3262
REC-1 CTRP2 5.0703 6.452 4.8477 7.2964
GR-ST GDSC1; GDSC2 5.0761 19.2576 -4.9956 20.6166
CMK GDSC1; CTRP2 5.0767 6.0384 4.9899 6.7349
OCI-Ly10 CTRP2 5.1204 7.0392 4.66 7.8892
HL-60 GDSC1; GDSC2; CTRP2 5.178 6.6512 4.8844 6.8405
SIG-M5 GDSC2; CTRP2 5.198 5.7623 5.1797 5.7008
OCI-AML-5 GDSC1; CTRP2 5.2371 5.8561 5.2067 5.47
HEL 92.1.7 CTRP2 5.2384 6.0515 5.1628 5.6344
OCI-M1 GDSC1; GDSC2; CTRP2 5.3909 6.0334 5.3342 4.5415
SU-DHL-4 GDSC1; GDSC2; CTRP2 5.4288 9.0273 4.0132 9.7814
H9 GDSC1; GDSC2 6.3837 26.2385 -7.4629 24.5403
Kasumi-1 GDSC1; GDSC2 6.6648 27.4131 -7.8353 24.8611
MC116 GDSC1; GDSC2; CTRP2 7.3267 8.1018 5.7953 0.0611
AMO1 GDSC1; GDSC2; CTRP2 7.4188 8.8269 5.5637 0.4719
MOLM-16 GDSC1; GDSC2; CTRP2 8.0593 10.3927 5.2315 0.9864
KMM-1 CTRP2 9.2961 11.6816 5.265 0.3531
⏷ Show the Full List of 214 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 1.2854 8.9447 -0.1527 35.7904
TE8 CTRP2 2.7196 9.2907 1.2076 27.4204
TE-15 GDSC1 -2.0388 1.588 -3.2364 21.4974
OE21 GDSC1; GDSC2; CTRP2 -0.9892 5.1024 -1.3963 47.1577
TE-6 GDSC1; GDSC2; CTRP2 0.1784 6.1956 -0.3993 40.3856
TE-4 GDSC1; GDSC2; CTRP2 0.5601 4.3565 0.4213 36.8792
T.T GDSC1; GDSC2 0.8086 6.8808 -2.1014 19.3458
KYSE-270 GDSC1; GDSC2 0.9241 5.9202 -1.5236 15.8562
TE-14 CTRP2 1.0563 5.9812 0.6178 34.5937
KYSE-140 GDSC1; GDSC2; CTRP2 1.0655 7.3609 0.2018 35.6215
TE-11 GDSC1; GDSC2; CTRP2 1.4068 5.8849 1.0259 32.0694
KYSE-410 GDSC1; GDSC2; CTRP2 1.9691 5.9559 1.6207 28.2733
KYSE-30 CTRP2 2.6198 9.5371 0.998 28.3834
KYSE-70 GDSC1; GDSC2; CTRP2 2.7358 6.7493 2.2192 23.8105
TE-10 GDSC1; GDSC2; CTRP2 2.9324 7.0906 2.3143 22.8839
TE-8 GDSC1; GDSC2 3.129 7.6015 -0.7404 6.0768
COLO 680N GDSC1; GDSC2; CTRP2 3.1929 7.3968 2.4812 21.5164
KYSE-180 GDSC1; GDSC2; CTRP2 3.5402 11.7759 0.8949 26.0941
TE-9 GDSC1; GDSC2; CTRP2 3.5929 5.0212 3.5636 16.3936
OE33 GDSC1; GDSC2; CTRP2 3.9464 6.9888 3.4419 15.773
TE-1 GDSC1; GDSC2; CTRP2 4.0015 8.7276 2.7689 18.2206
TE-5 GDSC1; GDSC2; CTRP2 4.169 5.8081 4.057 12.8519
KYSE-520 GDSC1; GDSC2; CTRP2 4.6095 10.1978 2.6773 17.071
KYSE-150 GDSC1; GDSC2; CTRP2 4.9538 9.1667 3.5018 12.9586
EC-GI-10 GDSC1; GDSC2; CTRP2 5.1528 12.5844 2.0046 18.4012
KYSE-510 GDSC1; GDSC2; CTRP2 5.5628 10.276 3.515 11.5573
OE19 GDSC1; GDSC2; CTRP2 7.8966 20.9368 0.0798 19.4419
KYSE-450 GDSC1; GDSC2; CTRP2 8.6915 19.3169 1.4639 13.8541
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 6.9923 14.2522 2.7012 12.1509
HuP-T4 GDSC1; GDSC2; CTRP2 0.8671 4.5123 0.7268 34.8608
PL4 GDSC1; GDSC2 1.9991 4.6313 -0.0658 4.3196
BxPC-3 GDSC1; GDSC2; CTRP2 2.6195 6.1143 2.2874 23.9195
KP-1N GDSC1; GDSC2 2.7125 5.6053 -0.0807 3.1694
HPAC GDSC1; GDSC2; CTRP2 2.9129 4.5456 2.8912 20.8878
SU.86.86 GDSC1; GDSC2; CTRP2 3.0417 4.068 3.0402 19.964
Panc 03.27 GDSC1; GDSC2; CTRP2 3.0963 8.3949 1.9795 23.6276
SNU-213 CTRP2 3.1806 4.8137 3.1497 19.1828
KP-3 GDSC1; GDSC2; CTRP2 3.4267 5.9551 3.2115 18.1484
Panc 08.13 GDSC1; GDSC2; CTRP2 3.4754 7.0536 2.9124 19.1032
Panc 10.05 GDSC1; GDSC2; CTRP2 3.5252 9.0288 2.15 21.8233
L3.3 CTRP2 3.5509 9.6319 1.9052 22.6979
Panc 05.04 CTRP2 3.5618 12.3164 0.658 26.8167
YAPC GDSC1; GDSC2; CTRP2 3.6032 5.6291 3.4811 16.6458
MZ-PC-1 GDSC1; GDSC2 3.6471 6.1699 0.1483 1.091
CFPAC-1 GDSC1; GDSC2; CTRP2 3.7394 5.536 3.6472 15.6362
PK-59 CTRP2 4.0573 6.7822 3.6375 14.7543
QGP-1 GDSC1; GDSC2; CTRP2 4.0684 6.4537 3.7638 14.2175
KP-4 GDSC1; GDSC2; CTRP2 4.2955 5.516 4.2497 11.7802
SUIT-2 GDSC1; GDSC2; CTRP2 4.3281 5.6681 4.259 11.6445
SW1990 GDSC1; GDSC2; CTRP2 4.3474 6.7186 3.9728 12.6325
Capan-2 GDSC1; GDSC2; CTRP2 4.3838 7.5287 3.6873 13.6308
TCC-Pan2 CTRP2 4.4777 7.2049 3.9209 12.4985
PaTu 8988s CTRP2 4.5142 8.6367 3.325 14.7638
Hs 766T GDSC1; GDSC2; CTRP2 4.7686 11.5959 2.1449 18.7442
KP-2 GDSC1; GDSC2; CTRP2 4.8386 7.1899 4.3039 10.0114
SNU-410 CTRP2 4.863 18.044 -0.9663 28.0314
HPAF-II GDSC1; GDSC2; CTRP2 5.0128 8.487 3.8842 11.2619
MIA PaCa-2 GDSC1; GDSC2; CTRP2 5.0208 6.2372 4.8693 7.3419
PaTu 8902 GDSC1; GDSC2; CTRP2 5.0971 6.4527 4.8761 7.0966
Panc 02.03 GDSC1; GDSC2; CTRP2 5.122 6.0483 5.0367 6.429
HuP-T3 GDSC1; GDSC2; CTRP2 5.2413 6.7339 4.9164 6.5459
Capan-1 GDSC1; GDSC2; CTRP2 5.3343 6.4554 5.1284 5.4728
PANC-1 CTRP2 5.3696 6.1017 5.2915 4.7708
PaTu 8988t GDSC1; GDSC2; CTRP2 5.4475 5.9947 5.4059 4.1114
PSN1 GDSC1; GDSC2; CTRP2 5.4633 6.5272 5.2351 4.7097
AsPC-1 GDSC1; GDSC2; CTRP2 5.4725 9.3353 3.901 10.1513
DAN-G GDSC1; GDSC2; CTRP2 7.1769 18.2464 0.8596 18.3352
PK-45H CTRP2 8.151 10.4176 5.2645 0.8384
Panc 04.03 GDSC1; GDSC2; CTRP2 9.9577 21.9681 1.0605 13.3429
⏷ Show the Full List of 41 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 76 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 2.0284 4.6232 1.9521 27.0126
A-431 GDSC1; GDSC2 0.8664 6.4177 -1.8209 17.6852
A-388 GDSC1; GDSC2 0.8799 6.1965 -1.699 16.9756
Hs 938.T GDSC1; GDSC2 1.7824 3.5392 0.3081 2.5515
VMRC-MELG GDSC1; GDSC2 1.888 4.3428 -0.0019 4.1632
451Lu GDSC1; GDSC2 1.9751 3.9202 0.2503 2.5403
LB2518-MEL GDSC1; GDSC2 2.074 5.2926 -0.3307 5.7389
CHL-1 GDSC1; GDSC2 2.1672 10.9619 -3.0448 19.9464
Malme-3M CTRP2 2.222 5.4391 2.0212 26.1527
MZ-MEL-2 GDSC1; GDSC2 2.2932 4.6565 0.1039 2.8257
G-361 GDSC1; GDSC2; CTRP2 2.4677 3.1322 2.4677 23.7744
SK-MEL-3 GDSC1; GDSC2; CTRP2 2.5078 2.9927 2.5078 23.5077
MMAc-SF GDSC1; GDSC2 2.5262 6.8802 -0.7861 7.4796
UACC-257 GDSC1; GDSC2; CTRP2 2.5354 2.9002 2.5354 23.3242
RVH-421 GDSC1; GDSC2; CTRP2 2.552 3.4089 2.5519 23.214
COLO 783 GDSC1; GDSC2 2.5666 3.9514 0.5374 0.5041
SK-MEL-24 GDSC1; GDSC2; CTRP2 2.5681 3.5971 2.5675 23.109
WM115 GDSC1; GDSC2; CTRP2 2.5731 2.8935 2.5731 23.0737
A101D GDSC1; GDSC2; CTRP2 2.5819 4.1406 2.5712 23.051
M14 GDSC1; GDSC2 2.6069 4.8645 0.1855 1.9526
COLO 792 GDSC1; GDSC2; CTRP2 2.6439 3.8913 2.6411 22.6124
Mel Ho GDSC1; GDSC2; CTRP2 2.6702 3.1288 2.6702 22.4282
WM266-4 CTRP2 2.6895 3.147 2.6895 22.3507
IGR-1 GDSC1; GDSC2; CTRP2 2.6928 4.4849 2.6665 22.3662
A2058 GDSC1; GDSC2; CTRP2 2.7003 3.1422 2.7003 22.2282
SK-MEL-5 GDSC1; GDSC2; CTRP2 2.7108 3.2738 2.7108 22.1583
HMV-II GDSC1; GDSC2 2.7285 6.966 -0.6949 6.5559
LB373-MEL-D GDSC1; GDSC2 2.7682 4.1499 0.5455 0.3669
Hs 940.T GDSC1; GDSC2; CTRP2 2.7884 4.0325 2.7848 21.6547
IPC-298 GDSC1; GDSC2; CTRP2 2.7933 3.4093 2.7933 21.6099
CP66-MEL GDSC1; GDSC2 2.796 4.1581 0.5534 0.3329
MZ-MEL-7 GDSC1; GDSC2 2.8317 4.3954 0.48 0.5231
GAK GDSC1; GDSC2 2.8403 3.9511 0.643 0.131
G-mel GDSC1; GDSC2 2.8509 5.1506 0.1889 1.6485
IGR-37 GDSC1; GDSC2; CTRP2 2.9246 4.5691 2.9017 20.814
SH-4 GDSC1; GDSC2 2.9277 5.6598 0.0128 2.3917
WM278 GDSC1; GDSC2 2.9626 6.7824 -0.4655 4.8529
DJM-1 GDSC1; GDSC2 2.9795 6.8738 -0.4971 4.9978
COLO 679 GDSC1; GDSC2 3.0599 4.8361 0.4086 0.6089
Mel JuSo GDSC1; GDSC2; CTRP2 3.0854 4.2063 3.0824 19.6784
WM1552C GDSC1; GDSC2 3.1001 4.7766 0.4472 0.4717
WM35 GDSC1; GDSC2 3.1072 9.8944 -1.8372 12.0312
SK-MEL-30 GDSC1; GDSC2; CTRP2 3.1607 4.0097 3.1603 19.1694
RPMI-7951 GDSC1; GDSC2; CTRP2 3.2176 4.2768 3.2149 18.7985
CP50-MEL-B GDSC1; GDSC2 3.3067 4.7895 0.5213 0.2176
COLO 741 CTRP2 3.331 19.0128 -2.8199 35.0393
Hs 936.T CTRP2 3.3536 4.7643 3.3344 17.991
SK-MEL-28 GDSC1; GDSC2; CTRP2 3.4801 4.547 3.4752 17.0612
WM793 GDSC1; GDSC2; CTRP2 3.5069 5.1406 3.4594 17.027
SK-MEL-1 GDSC1; GDSC2; CTRP2 3.5562 4.4265 3.5547 16.5441
IST-MEL1 GDSC1; GDSC2 3.6054 5.5162 0.3758 0.4241
MDA-MB-435S CTRP2 3.6382 5.2078 3.5906 16.1917
WM1799 CTRP2 3.7245 5.3052 3.6694 15.6427
MeWo GDSC1; GDSC2; CTRP2 3.7974 5.6044 3.6968 15.28
K029AX CTRP2 4.0255 4.7254 4.0244 13.454
COLO 829 GDSC1; GDSC2; CTRP2 4.1522 6.5913 3.8078 13.8105
WM983B CTRP2 4.2105 5.8853 4.0841 12.6563
LOX-IMVI GDSC1; GDSC2; CTRP2 4.2562 5.5531 4.2017 12.0715
HT-144 GDSC1; GDSC2; CTRP2 4.2972 5.2855 4.279 11.6747
Hs 944.T CTRP2 4.3025 6.0909 4.1306 12.2076
UACC-62 GDSC1; GDSC2; CTRP2 4.4352 4.9477 4.4347 10.6982
COLO 800 GDSC1; GDSC2; CTRP2 4.4893 6.0788 4.3378 10.8667
WT2-iPS GDSC1; GDSC2; CTRP2 4.5767 5.3263 4.5676 9.7863
CJM [Human melanoma] CTRP2 4.608 5.3533 4.5983 9.6019
A-375 GDSC1; GDSC2; CTRP2 4.6245 6.3086 4.4154 10.1801
Hs 688(A).T CTRP2 4.6311 6.2582 4.4387 10.0978
Hs 294T CTRP2 4.6769 5.7806 4.6149 9.3231
WM88 CTRP2 4.7268 5.5262 4.7078 8.8422
HMCB CTRP2 4.7429 5.8529 4.6714 8.9172
SK-MEL-31 GDSC1; GDSC2; CTRP2 4.8875 5.8792 4.8228 7.9126
IGR-39 CTRP2 4.9153 6.0712 4.8048 7.9096
Hs 852.T CTRP2 4.9488 6.7001 4.6225 8.4967
Hs 895.T CTRP2 5.0807 6.6501 4.7822 7.5179
SK-MEL-2 GDSC1; GDSC2; CTRP2 5.2816 5.8282 5.2595 5.1453
Hs 839.T CTRP2 5.3297 5.945 5.2891 4.9016
EquiPSC Line K2 GDSC1; GDSC2 1.8685 3.9586 0.1667 3.2093
⏷ Show the Full List of 76 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYAE-1 GDSC1; GDSC2 -3.3816 3.2807 -4.5528 45.8178
SK-GT-4 GDSC1; GDSC2 0.8877 5.6832 -1.4359 15.4632
KYSE-220 GDSC1; GDSC2 1.2699 7.0081 -1.7822 16.2802
TE-12 GDSC1; GDSC2 1.3898 10.2924 -3.3255 23.1778
HCE-4 GDSC1; GDSC2 2.4802 5.3059 -0.0802 3.5325
KYSE-50 GDSC1; GDSC2 3.0078 10.7299 -2.3102 14.6012
OACP4 C GDSC1; GDSC2 3.0953 7.1145 -0.5379 5.0275
OACM5.1 C GDSC1; GDSC2 3.1503 10.0985 -1.9059 12.2903
FLO-1 GDSC1; GDSC2 3.1889 6.8329 -0.3575 3.9163
ESO-26 GDSC1; GDSC2 3.3465 9.3063 -1.3983 9.2462
ESO-51 GDSC1; GDSC2 3.5152 5.2432 0.439 0.3148
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; GDSC2; CTRP2 5.1897 6.6105 4.9133 6.697
Cancer Drug Sensitivity Data Curated from 35 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NB69 GDSC1; GDSC2 0.3587 8.1871 -3.141 25.559
SK-N-DZ GDSC1; GDSC2 0.6354 4.8819 -1.2526 15.1735
SJNB-10 GDSC1; GDSC2 2.1405 6.3115 -0.7758 8.2463
SK-N-MC-IXC GDSC1; GDSC2 2.3521 3.3797 0.663 0.2526
NB(TU)1 GDSC1; GDSC2 2.5094 12.7018 -3.6455 21.4911
SJNB-14 GDSC1; GDSC2 2.5575 4.7585 0.2051 1.9195
LA-N-6 GDSC1; GDSC2 2.6267 5.3539 -0.0173 2.9622
SJNB-12 GDSC1; GDSC2 2.627 6.1683 -0.3869 4.996
SJNB-5 GDSC1; GDSC2 2.7588 8.5873 -1.4468 10.7111
TGW GDSC1; GDSC2 2.8157 4.4753 0.4431 0.6535
SJNB-6 GDSC1; GDSC2 2.8259 4.4639 0.4518 0.6175
GOTO GDSC1; GDSC2 2.863 6.5428 -0.4158 4.7467
CHP-126 GDSC1; GDSC2 2.8976 4.4921 0.4709 0.5125
NH-12 GDSC1; GDSC2 2.9374 11.5305 -2.7509 16.8032
KP-N-YN GDSC1; GDSC2 2.9405 5.258 0.1883 1.5549
SK-N-BE(2)-M17 GDSC1; GDSC2 2.9508 4.8903 0.3411 0.9186
Kelly GDSC1; GDSC2; CTRP2 2.9959 4.1454 2.9928 20.2735
CHP-134 GDSC2 3.0346 4.8093 0.4083 0.6278
SJNB-13 GDSC1; GDSC2 3.0639 5.0858 0.3146 0.9283
KP-N-YS GDSC1; GDSC2 3.1548 12.7089 -3.1703 18.1089
IMR-5 GDSC1; GDSC2 3.1848 4.9463 0.4185 0.5088
SJNB-7 GDSC1; GDSC2 3.2648 5.2515 0.3371 0.7099
SiMa GDSC1; GDSC2 3.4862 5.3785 0.3794 0.4673
SJNB-17 GDSC1; GDSC2 3.5446 5.4619 0.3719 0.4601
MHH-NB-11 GDSC1; GDSC2; CTRP2 3.7013 5.3914 3.6314 15.812
SK-N-BE(2) CTRP2 3.7442 5.8536 3.5836 15.8816
KP-N-RT-BM-1 GDSC2 3.7487 6.4374 0.0887 1.2345
SK-N-FI GDSC1; GDSC2; CTRP2 3.971 6.2099 3.7344 14.6135
SK-N-SH GDSC1; GDSC2; CTRP2 4.0015 5.0879 3.9859 13.6312
GI-ME-N GDSC1; GDSC2 4.0033 10.1322 -1.3723 7.9165
KP-N-SI9s CTRP2 4.0585 5.4382 4.0075 13.4034
CHP-212 GDSC1; GDSC2; CTRP2 4.101 5.8885 3.9639 13.3927
NB1 GDSC1; GDSC2; CTRP2 4.2752 5.7362 4.1882 12.0584
NH-6 CTRP2 4.4913 6.148 4.32 10.95
SK-N-AS GDSC1; GDSC2; CTRP2 4.7566 5.8466 4.6876 8.7973
⏷ Show the Full List of 35 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1079 CTRP2 -3.3004 3.0922 -3.5258 60.437
SNU-478 CTRP2 -0.9855 6.4403 -1.7392 47.4555
SNU-308 CTRP2 1.2579 5.1429 1.0364 32.6128
HuCC-T1 GDSC1; GDSC2; CTRP2 1.8315 5.58 1.5647 28.9047
HuH-28 CTRP2 3.5817 4.9935 3.5545 16.4983
SNU-1196 CTRP2 3.6538 8.1835 2.6501 19.6425
SNU-869 CTRP2 4.7188 5.9059 4.6331 9.1283
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 88 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MDA-MB-175-VII GDSC1; GDSC2 -0.9677 1.9872 -1.4794 22.4429
AU565 GDSC1; GDSC2; CTRP2 0.4643 4.9601 0.2127 37.8201
SK-BR-3 CTRP2 1.2975 6.5968 0.7033 33.4992
BT-474 GDSC1; GDSC2; CTRP2 1.5102 5.476 1.239 31.0385
HCC2157 GDSC1; GDSC2 1.5945 7.9151 -1.9754 16.4056
CAL-85-1 GDSC1; GDSC2; CTRP2 1.6969 5.4472 1.4486 29.7314
MDA-MB-330 GDSC1; GDSC2 1.7447 5.3423 -0.5861 8.0223
MDA-MB-468 GDSC1; GDSC2; CTRP2 1.9792 5.7927 1.674 28.0596
ZR-75-30 GDSC1; GDSC2; CTRP2 2.0437 3.9823 2.0249 26.6554
HCC1954 GDSC1; GDSC2; CTRP2 2.0749 6.2795 1.6459 27.8519
HCC1569 GDSC1; GDSC2 2.2102 5.044 -0.1244 4.2569
HCC1806 GDSC1; GDSC2; CTRP2 2.2938 7.2496 1.5687 27.433
UACC-812 GDSC2 2.3445 4.5049 0.2006 2.2393
UACC-893 GDSC1; GDSC2 2.4839 6.1004 -0.4451 5.5926
CAL-120 GDSC1; GDSC2 2.5307 4.3513 0.3628 1.213
DU4475 GDSC1; GDSC2; CTRP2 2.5881 3.0866 2.5881 22.9741
EFM-192A GDSC1; GDSC2; CTRP2 2.5922 4.3881 2.5686 23.026
HCC1419 GDSC1; GDSC2; CTRP2 2.6197 4.8113 2.5573 22.9743
BT-483 GDSC1; GDSC2 2.6448 6.4304 -0.4975 5.5909
COLO 824 GDSC1; GDSC2 2.793 6.0035 -0.2126 3.7516
HCC1187 GDSC1; GDSC2 2.9248 4.4316 0.5043 0.4021
MDA-MB-361 GDSC1; GDSC2; CTRP2 2.9259 7.6563 2.0967 23.6918
MRK-nu-1 GDSC1; GDSC2 3.0191 4.2555 0.6022 0.1535
HCC1500 GDSC1; GDSC2; CTRP2 3.1522 5.8612 2.9362 19.9733
HDQ-P1 GDSC1; GDSC2; CTRP2 3.1801 10.3076 1.2249 26.0028
Evsa-T GDSC1; GDSC2 3.2891 4.5957 0.5815 0.1253
OCUB-M GDSC1; GDSC2 3.3799 5.0977 0.4397 0.3639
MDA-MB-453 GDSC1; GDSC2; CTRP2 3.3883 5.3492 3.3017 17.9498
HCC1599 GDSC2 3.3894 5.3008 0.3696 0.5427
MDA-MB-415 GDSC1; GDSC2; CTRP2 3.4264 6.0579 3.1836 18.2492
HCC70 GDSC1; GDSC2 3.471 10.75 -2.0013 12.1011
HCC1395 GDSC1; GDSC2; CTRP2 3.5751 4.9904 3.5478 16.5052
HCC1143 GDSC1; GDSC2; CTRP2 3.6025 8.5753 2.4285 20.5764
HMC-1-8 CTRP2 3.6541 4.4836 3.6528 15.9288
MFM-223 GDSC1; GDSC2 3.7024 5.1359 0.5426 0.1028
YMB-1-E GDSC2 3.7458 6.0579 0.2326 0.7497
HCC2218 GDSC1; GDSC2 3.7574 21.7441 -7.1732 28.4741
CAL-51 GDSC1; GDSC2; CTRP2 3.8308 5.9488 3.6541 15.3277
JIMT-1 GDSC1; GDSC2; CTRP2 3.8608 5.1213 3.8358 14.5984
T-47D GDSC1; GDSC2; CTRP2 3.8751 7.4023 3.2053 16.8723
Hs 578T GDSC1; GDSC2 3.906 6.709 0.052 1.2442
Hs 578Bst CTRP2 4 5.7902 3.8772 14.0445
MDA-MB-436 GDSC1; GDSC2 4.0334 5.8889 0.4031 0.2294
MDA-MB-231 GDSC1; GDSC2; CTRP2 4.0651 5.6858 3.9706 13.4806
HCC1937 GDSC1; GDSC2; CTRP2 4.1014 11.3869 1.6207 22.2472
MCF-7 GDSC1; GDSC2; CTRP2 4.1849 5.4019 4.1476 12.4859
EFM-19 GDSC1; GDSC2 4.2147 6.2399 0.3471 0.2775
CAL-148 GDSC2; CTRP2 4.3263 7.0084 3.8399 13.2264
CAMA-1 GDSC1; GDSC2; CTRP2 4.6017 5.9712 4.4893 9.9797
HCC1428 GDSC1; GDSC2; CTRP2 4.7358 5.5636 4.7131 8.7746
ZR-75-1 CTRP2 5.0728 6.6146 4.7879 7.5174
BT-20 GDSC1; GDSC2; CTRP2 5.1772 6.772 4.8335 7.0406
HCC202 GDSC1; CTRP2 5.3026 8.8472 3.9852 10.1777
MDA-MB-157 GDSC1; GDSC2; CTRP2 5.5096 16.8608 0.1843 23.6153
HCC38 GDSC1; GDSC2; CTRP2 8.0812 10.4931 5.2009 1.0602
BT-549 GDSC1; GDSC2; CTRP2 8.0989 10.0041 5.4037 0.5154
BT 145 CTRP2 1.4324 4.5594 1.3252 31.0831
BT 428 CTRP2 2.3494 10.4631 0.3141 31.1963
BT147 CTRP2 2.503 7.7288 1.6173 26.6895
BT 248 CTRP2 2.6962 5.7934 2.4558 23.1385
BT 139 CTRP2 2.7126 8.2905 1.6193 26.0587
BT 231 CTRP2 2.7727 5.7742 2.5439 22.5891
BT 330 CTRP2 2.7909 7.5662 1.987 24.5346
BT 440 CTRP2 2.7944 4.5588 2.7669 21.7443
BT 286 CTRP2 2.8697 4.6221 2.8404 21.2487
BT 159 CTRP2 3.0383 5.6156 2.8701 20.6072
BT 239 CTRP2 3.0808 7.1748 2.4437 22.0274
BT 131 CTRP2 3.1151 5.5693 2.9636 20.0371
BT 216 CTRP2 3.1367 6.0934 2.8576 20.3481
BT 504 CTRP2 3.1653 5.6981 2.9897 19.7878
BT 271 CTRP2 3.1876 10.5191 1.1357 26.3275
BT 172 CTRP2 3.2033 8.1786 2.1814 22.6428
BT 179 CTRP2 3.4531 6.6708 3.0236 18.7969
BT 228 CTRP2 3.4982 5.2088 3.4412 17.1564
BT 232 CTRP2 3.5185 9.3268 2.0103 22.4032
BT 187 CTRP2 3.6511 8.2203 2.6316 19.7206
BT 340 CTRP2 3.752 5.9106 3.5779 15.8778
BT 359 CTRP2 3.8776 10.2666 1.9368 21.7275
BT164 CTRP2 4.0303 6.4106 3.7364 14.4632
BT 245 CTRP2 4.6003 7.1831 4.0586 11.6311
BT 224 CTRP2 4.6444 5.9318 4.5457 9.6696
BT 482 CTRP2 4.8241 6.2174 4.6617 8.7055
BT 422 CTRP2 4.8988 11.7123 2.207 18.2513
BT 320 CTRP2 4.9799 8.7684 3.7182 12.0435
BT 333 CTRP2 5.0606 11.237 2.5886 16.4163
BT 328 CTRP2 5.2455 11.2873 2.7306 15.4479
BT 498 CTRP2 7.2917 8.4139 5.6687 0.2837
BT 444 CTRP2 8.1523 9.1592 5.7244 0.0305
⏷ Show the Full List of 88 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 -2.7373 0.5995 -2.7467 58.3701
Cancer Drug Sensitivity Data Curated from 68 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNZTA3WT4 GDSC1 1.3533 2.8761 -1.4919 0.2856
GI-1 GDSC1; GDSC2 2.1706 5.7161 -0.4683 6.355
SF539 GDSC1; GDSC2; CTRP2 2.4819 3.3663 2.4818 23.6805
LN-405 GDSC1; GDSC2 2.5635 4.8706 0.16 2.1358
42-MG-BA GDSC1; GDSC2; CTRP2 2.6225 5.1769 2.506 23.1418
Hs 683 GDSC1; GDSC2; CTRP2 2.6296 3.1638 2.6296 22.6984
PFSK-1 GDSC1; GDSC2 2.8542 8.4764 -1.3287 9.8616
D-566MG GDSC1; GDSC2 2.8649 4.512 0.4499 0.5983
SF268 GDSC1; GDSC2; CTRP2 2.8841 5.1638 2.7898 21.327
D-502MG GDSC1; GDSC2 2.8842 5.2753 0.1534 1.7738
D-263MG GDSC1; GDSC2 2.9839 4.6575 0.4444 0.5434
CAS-1 GDSC1; GDSC2 3.0039 4.4797 0.5176 0.3317
SNU-466 CTRP2 3.0306 3.7081 3.0306 20.0785
D-542MG GDSC1; GDSC2 3.0579 5.0943 0.3086 0.9552
D-336MG GDSC1; GDSC2 3.0874 6.4848 -0.2602 3.5578
SK-MG-1 GDSC1; GDSC2 3.103 4.7851 0.4452 0.4757
Onda 11 GDSC1; GDSC2 3.2762 5.407 0.2825 0.8859
KNS-60 CTRP2 3.2832 4.6839 3.2667 18.4507
D-245MG GDSC2 3.3083 6.5856 -0.1847 2.8835
MOG-G-UVW GDSC1; GDSC2 3.3423 5.1786 0.3958 0.492
M059J GDSC1; GDSC2 3.4607 5.4211 0.3537 0.5486
KNS-81 CTRP2 3.4976 5.3616 3.4172 17.2412
DK-MG GDSC1; GDSC2 3.5046 4.6023 0.6521 0.0331
D-423MG GDSC1; GDSC2 3.577 6.7325 -0.1101 2.206
D-392MG GDSC1; GDSC2 3.5876 5.8628 0.2405 0.8177
D-247MG GDSC1; GDSC2 3.6454 6.868 -0.1327 2.2335
SNB-75 GDSC1; GDSC2; CTRP2 3.7059 7.6964 2.9077 18.4748
U-251MG GDSC1; GDSC2; CTRP2 3.7224 5.6451 3.6071 15.8302
LN-229 GDSC1; GDSC2; CTRP2 3.732 7.362 3.0695 17.7869
MOG-G-CCM GDSC1; GDSC2 3.7454 6.0267 0.2441 0.7127
LN-18 GDSC1; GDSC2; CTRP2 3.7551 4.369 3.7549 15.2177
DBTRG-05MG GDSC1; GDSC2; CTRP2 3.8652 5.1572 3.837 14.5801
Daoy GDSC1; GDSC2; CTRP2 3.8862 5.2222 3.8522 14.4601
Onda 10 GDSC1; GDSC2 3.8964 5.5519 0.4697 0.1596
ONS-76 GDSC1; GDSC2; CTRP2 3.9246 5.4293 3.8652 14.2921
SNU-1105 CTRP2 3.9314 4.7324 3.9291 14.0847
H4 GDSC1; GDSC2 3.9499 5.8831 0.3749 0.3025
AM-38 GDSC1; GDSC2; CTRP2 3.9921 5.2608 3.9599 13.75
KINGS-1 GDSC1; GDSC2 4.0477 5.954 0.3858 0.2549
SW1783 GDSC1; GDSC2 4.0529 6.3109 0.2616 0.5138
U-87MG ATCC GDSC1; GDSC2; CTRP2 4.0697 4.9868 4.0624 13.1501
SF126 GDSC1; GDSC2; CTRP2 4.1025 5.3256 4.0695 13.0191
SNU-201 CTRP2 4.111 5.3087 4.0804 12.9839
GB-1 GDSC1; GDSC2; CTRP2 4.1169 5.858 3.9886 13.2556
SNU-626 CTRP2 4.1244 5.762 4.0188 13.1557
D283 Med GDSC1; GDSC2; CTRP2 4.1541 5.2938 4.1277 12.6538
NMC-G1 GDSC1; GDSC2; CTRP2 4.1673 5.148 4.1542 12.5207
T98G GDSC1; GDSC2; CTRP2 4.1731 6.7061 3.7897 13.818
SNU-489 CTRP2 4.4294 5.6063 4.3793 10.9303
SW1088 GDSC1; GDSC2; CTRP2 4.4308 6.3063 4.2056 11.5232
GaMG GDSC1; GDSC2; CTRP2 4.44 6.0748 4.285 11.2064
KS-1 [Human Krukenberg tumour] GDSC1; GDSC2 4.4833 7.1562 0.1226 0.675
SNU-738 CTRP2 4.6117 6.6485 4.2825 10.7384
TM-31 CTRP2 4.6366 5.3179 4.6301 9.4005
KNS-42 GDSC1; GDSC2; CTRP2 4.7358 5.88 4.6576 8.9679
KALS-1 GDSC1; GDSC2; CTRP2 4.7509 6.3325 4.5447 9.3321
SF295 GDSC1; GDSC2; CTRP2 4.8522 13.2741 1.3936 21.2512
A-172 GDSC1; GDSC2; CTRP2 4.9325 6.8447 4.5469 8.8131
GMS-10 CTRP2 4.9557 5.6217 4.9395 7.3077
U-118MG GDSC1; GDSC2; CTRP2 4.9599 7.7338 4.1852 10.1723
GOS-3 CTRP2 5.1128 6.2294 4.9718 6.7086
M059K CTRP2 5.1897 6.5867 4.9229 6.6753
CCF-STTG1 CTRP2 5.2274 7.4044 4.6036 7.8424
Becker GDSC1; GDSC2; CTRP2 5.2551 8.9227 3.9042 10.6188
YH-13 GDSC1; GDSC2; CTRP2 5.3613 6.5252 5.1289 5.3967
YKG-1 GDSC1; GDSC2; CTRP2 5.3995 5.9335 5.3675 4.3967
KNS-81-FD GDSC1; GDSC2 5.6047 16.4406 -3.3033 13.8617
8-MG-BA GDSC1; GDSC2; CTRP2 5.6571 6.4875 5.4526 3.345
⏷ Show the Full List of 68 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC1; GDSC2 0.506 6.9747 -2.4084 21.8368
TGBC24TKB GDSC1; GDSC2 0.6039 5.6324 -1.6541 17.5876
TGBC1TKB GDSC1; GDSC2 2.5626 6.4853 -0.5754 6.1923
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RL95-2 GDSC1; GDSC2; CTRP2 1.8249 8.8362 0.4616 32.3569
HEC-1-A CTRP2 2.392 6.1869 2.0186 25.6276
JHUEM-3 CTRP2 2.8591 6.1651 2.5345 22.3564
JHUEM-2 CTRP2 3.1128 4.7825 3.0814 19.6364
HEC-1-B CTRP2 3.495 10.3083 1.5392 24.1417
HEC-6 CTRP2 3.5575 4.6202 3.5519 16.5868
MFE-319 GDSC1; GDSC2; CTRP2 3.5751 6.2992 3.2759 17.4671
HEC-251 CTRP2 3.5846 7.4348 2.8842 18.9429
AN3-CA GDSC1; GDSC2; CTRP2 3.7469 5.9153 3.5711 15.8817
HEC-108 CTRP2 3.7674 4.9571 3.7514 15.2234
MFE-296 GDSC1; GDSC2; CTRP2 3.8881 5.8549 3.7401 14.8451
MFE-280 GDSC1; GDSC2 4.0239 6.4178 0.2114 0.6586
HEC-59 CTRP2 4.0919 5.4133 4.0469 13.1606
JHUEM-1 CTRP2 4.2741 6.0557 4.1094 12.3704
HEC-265 CTRP2 4.6701 6.3208 4.4609 9.901
EFE-184 CTRP2 4.6827 12.0026 1.8662 20.0143
HEC-151 CTRP2 4.9656 9.8379 3.1877 14.2385
EN GDSC1; GDSC2; CTRP2 5.3503 5.9814 5.3032 4.7766
ESS-1 GDSC1; GDSC2; CTRP2 5.3614 6.1851 5.2563 4.9136
HEC-50B CTRP2 6.1555 8.9351 4.6906 5.4796
KLE GDSC1; GDSC2; CTRP2 8.7657 17.6982 2.2999 10.8324
Ishikawa (Heraklio) 02 ER- CTRP2 4.2818 6.4487 3.997 12.7596
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW13 GDSC1; GDSC2 1.1863 3.7303 -0.2132 7.1299
CAL-54 GDSC1; GDSC2; CTRP2 1.2545 9.2321 -0.3007 36.165
KTCTL-1M GDSC1; GDSC2 1.7977 8.4405 -2.0782 16.3914
LB2241-RCC GDSC1; GDSC2 1.8876 6.7071 -1.1519 11.0592
KMRC-3 CTRP2 1.981 4.8932 1.8629 27.4708
NCC021 GDSC1; GDSC2 2.0478 4.4295 0.0599 3.4939
UO-31 GDSC1; GDSC2; CTRP2 2.0753 4.9252 1.9591 26.7758
TK-10 GDSC1; GDSC2 2.1497 8.8206 -1.9984 15.0752
KTCTL-13 GDSC1; GDSC2 2.1659 5.1084 -0.1828 4.6803
LB996-RCC GDSC2 2.2136 8.4905 -1.7883 13.8567
KTCTL-140 GDSC1; GDSC2 2.2278 14.0567 -4.5355 25.2219
TUHR10TKB CTRP2 2.2322 3.6435 2.2288 25.4088
A-704 GDSC1; GDSC2 2.2522 4.291 0.2436 2.14
HA7-RCC GDSC1; GDSC2 2.2932 5.7425 -0.3995 5.699
LB1047-RCC GDSC1; GDSC2 2.3001 8.9809 -1.9656 14.5341
SW156 GDSC1; GDSC2 2.547 8.6303 -1.6154 12.0981
KTCTL-21 GDSC1; GDSC2 2.6383 5.767 -0.1962 3.9112
NCC010 GDSC1; GDSC2 2.6755 5.659 -0.1257 3.4671
VMRC-RCW GDSC1; GDSC2; CTRP2 2.7472 3.9323 2.7448 21.9244
SN12C GDSC1; GDSC2 2.771 4.785 0.3005 1.24
KTCTL-195 GDSC1; GDSC2 3.0816 5.9167 -0.0169 2.3433
KTCTL-26A GDSC1; GDSC2 3.1774 7.6092 -0.7145 5.8514
TUHR4TKB CTRP2 3.2294 4.2045 3.2279 18.759
BB65-RCC GDSC1; GDSC2 3.3605 5.6484 0.2257 1.0265
VMRC-RCZ GDSC1; GDSC2; CTRP2 3.8256 6.4105 3.514 15.8521
KMRC-20 GDSC1; GDSC2; CTRP2 3.9707 5.1986 3.944 13.8739
RXF 393L GDSC1; GDSC2 3.9906 6.8708 0.0261 1.2741
769-P GDSC1; GDSC2; CTRP2 4.0027 12.2097 1.13 24.1581
BFTC-909 GDSC1; GDSC2; CTRP2 4.1059 5.5557 4.0395 13.1113
OS-RC-2 GDSC1; GDSC2; CTRP2 4.1209 6.1597 3.9126 13.5167
TUHR14TKB CTRP2 4.2341 7.301 3.6253 30.2503
KMRC-1 GDSC1; GDSC2; CTRP2 4.3631 5.1727 4.3555 11.201
786-O GDSC1; GDSC2; CTRP2 4.3993 5.7557 4.3188 11.211
KMRC-2 CTRP2 4.6397 7.1573 4.1105 11.3229
A-498 GDSC1; GDSC2; CTRP2 4.6569 5.8601 4.5762 9.5006
Caki-2 CTRP2 5.0003 8.7212 3.7604 11.8231
ACHN GDSC1; GDSC2; CTRP2 5.6537 13.3372 2.0675 17.0971
RCC10RGB GDSC1; GDSC2; CTRP2 7.0752 13.5071 3.1334 10.281
SNU-1272 CTRP2 8.0099 12.5551 4.2449 4.5017
Caki-1 GDSC1; GDSC2; CTRP2 8.1544 14.9172 3.2194 8.27
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 58 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DiFi GDSC1; GDSC2 -4.1469 -0.6632 -4.2657 51.3484
NCI-H508 GDSC1; GDSC2; CTRP2 -1.4615 3.8948 -1.6761 49.9011
SW48 GDSC1; GDSC2; CTRP2 -1.2239 9.4682 -3.029 48.9054
SNU-1033 CTRP2 -0.4595 49.8067 -21.4682 48.9158
CCK-81 GDSC1; GDSC2; CTRP2 -0.1537 5.1192 -0.4914 41.9655
SW1463 GDSC1; GDSC2; CTRP2 0.2421 5.9017 -0.2494 39.8122
HT115 GDSC1; GDSC2; CTRP2 0.6718 3.5557 0.6287 35.8506
SNU-175 GDSC2; CTRP2 1.3904 5.8415 1.0193 32.2172
NCI-H747 GDSC1; GDSC2; CTRP2 1.5722 5.0424 1.3963 30.3145
LoVo GDSC1; GDSC2; CTRP2 1.6379 6.2564 1.176 30.821
SNU-283 GDSC2 1.7702 5.7936 -0.7891 9.2233
T84 GDSC1; GDSC2; CTRP2 2.0659 5.6775 1.7969 27.3626
SNU-C4 CTRP2 2.1382 7.7673 1.2123 29.1629
GP5d GDSC1; GDSC2 2.1696 3.8513 0.3906 1.5028
SK-CO-1 GDSC1; GDSC2; CTRP2 2.2515 5.2604 2.0898 25.7621
HCT 15 GDSC1; GDSC2; CTRP2 2.5441 4.4586 2.5133 23.3698
HT-55 GDSC1; GDSC2; CTRP2 2.5513 5.8357 2.2871 24.1309
CaR-1 GDSC1; GDSC2 2.5551 5.376 -0.0681 3.3453
SNU-81 GDSC1; GDSC2 2.7169 4.6999 0.3095 1.255
SNU-61 GDSC1; GDSC2; CTRP2 2.74 8.5511 1.5414 26.1891
SNU-407 GDSC1; GDSC2; CTRP2 2.7727 7.3196 2.0594 24.2746
SW1116 GDSC1; GDSC2 2.8713 7.4606 -0.8357 7.0794
SW837 GDSC1; GDSC2 2.9559 5.5176 0.0878 1.9964
LS180 GDSC1; GDSC2; CTRP2 3.0878 5.6916 2.9068 20.277
COLO 320HSR GDSC1; GDSC2 3.1002 5.363 0.2213 1.2596
LS513 GDSC1; CTRP2 3.124 4.1824 3.1217 19.4196
HCT 8 CTRP2 3.1904 4.945 3.1468 19.161
C2BBe1 GDSC1; GDSC2; CTRP2 3.1954 9.4478 1.6277 24.5976
COLO 320 CTRP2 3.4795 7.68 2.6755 20.0267
HCC2998 GDSC1; GDSC2 3.5872 5.3768 0.4186 0.333
SNU-C2A CTRP2 3.5924 13.9221 -0.0868 28.8357
SNU-503 CTRP2 3.6541 10.537 1.5904 23.5431
RKO GDSC1; GDSC2; CTRP2 3.8758 5.4057 3.8166 14.6155
HT-29 GDSC1; GDSC2; CTRP2 3.9088 4.9964 3.8958 14.2387
CL-11 GDSC1; GDSC2; CTRP2 3.9717 6.4324 3.6657 14.8635
DLD-1 CTRP2 3.987 5.2108 3.96 13.7976
SNU-C1 GDSC1; GDSC2; CTRP2 4.069 5.9003 3.9262 13.6253
COLO205 GDSC1; GDSC2; CTRP2 4.0768 4.9016 4.0729 13.0916
COLO201 CTRP2 4.0934 5.3644 4.055 13.1277
OUMS-23 CTRP2 4.2352 5.607 4.1699 12.2764
SNU-C2B GDSC1; GDSC2 4.272 10.4013 -1.3349 7.2826
LS411N GDSC1; GDSC2; CTRP2 4.3872 5.2203 4.3777 11.0472
SW626 GDSC1; GDSC2 4.453 7.2631 0.0713 0.8315
SW620 GDSC1; GDSC2; CTRP2 4.5058 6.2229 4.3133 10.9061
LS1034 GDSC1; GDSC2; CTRP2 4.5071 6.5321 4.2121 11.277
HCT 116 GDSC1; GDSC2; CTRP2 4.5103 5.6063 4.4662 10.3469
COLO 678 GDSC1; GDSC2; CTRP2 4.5275 10.5381 2.4352 18.2063
SNU-C5 GDSC1; GDSC2; CTRP2 4.5811 7.4407 3.9296 12.1597
LS123 GDSC1; GDSC2; CTRP2 4.61 6.5926 4.3013 10.6477
SW1417 GDSC1; GDSC2; CTRP2 4.6246 6.3701 4.3952 10.2546
RCM-1 [Human ESC] GDSC1; GDSC2; CTRP2 4.8852 7.2294 4.335 9.7669
KM12 GDSC1; GDSC2; CTRP2 4.9491 6.3919 4.739 8.0343
NCI-H716 GDSC1; GDSC2; CTRP2 5.0361 6.6317 4.7422 7.7768
SW948 GDSC1; GDSC2; CTRP2 5.2507 6.0204 5.1846 5.5058
CW-2 GDSC1; GDSC2; CTRP2 5.4473 13.5789 1.7687 18.6242
HCC-56 CTRP2 5.7415 6.3477 5.6005 2.5469
GP2d CTRP2 6.434 14.854 1.9599 15.9762
MDST8 GDSC1; GDSC2; CTRP2 7.999 9.3261 5.614 0.1548
⏷ Show the Full List of 58 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1; GDSC2 2.1173 4.0886 0.2575 2.2695
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-5 CTRP2 0.2807 6.934 -0.5094 40.2714
JHH-6 GDSC1; GDSC2 1.354 5.9938 -1.2084 12.7851
SNU-182 CTRP2 1.6745 6.6788 1.0882 31.0497
Hep-G2/C3A GDSC1; GDSC2 2.0144 3.8631 0.2994 2.2041
SNU-761 CTRP2 2.3298 5.6862 2.0824 25.5985
JHH-1 GDSC1; GDSC2; CTRP2 2.3607 5.5333 2.1514 25.2026
SNU-878 CTRP2 2.4878 3.7764 2.4851 23.7033
HuH-6 CTRP2 2.7432 5.5695 2.5594 22.6264
Huh-7 GDSC1; GDSC2 2.9973 4.8758 0.367 0.7891
JHH-7 GDSC1; GDSC2 3.1724 4.8631 0.4441 0.4442
SNU-449 GDSC1; GDSC2; CTRP2 3.501 8.4873 2.3617 21.1018
Li-7 CTRP2 3.6186 6.8372 3.1449 17.864
Hep 3B2.1-7 GDSC1; GDSC2; CTRP2 3.6609 4.2411 3.6608 15.8436
HLE GDSC1; GDSC2 3.8256 5.9029 0.3212 0.4645
Hep-G2 CTRP2 3.8323 5.4263 3.7666 14.9609
PLC/PRF/5 CTRP2 4.0607 6.8196 3.6275 14.7824
SNU-886 CTRP2 4.2467 6.0761 4.0737 12.5827
HLF CTRP2 4.2808 5.6525 4.2108 11.9892
JHH-4 GDSC1; GDSC2; CTRP2 4.2954 6.7658 3.8995 13.0567
HuH-1 GDSC1; GDSC2; CTRP2 4.5752 7.3223 3.9739 12.0019
SNU-423 GDSC1; GDSC2; CTRP2 4.6682 6.0854 4.5311 9.6276
SK-HEP-1 GDSC1; GDSC2; CTRP2 5.2131 5.9933 5.1506 5.7424
SNU-387 GDSC1; GDSC2; CTRP2 5.2203 6.5412 4.9734 6.382
JHH-2 GDSC1; GDSC2; CTRP2 5.2377 6.8583 4.8595 6.7786
SNU-398 GDSC1; GDSC2; CTRP2 8.3155 9.8735 5.5387 0.1877
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 222 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC4006 CTRP2 -6.5618 1.7186 -6.8186 74.2035
HCC827 GDSC1; GDSC2; CTRP2 -6.394 0.0731 -6.4787 76.2043
NCI-H3255 GDSC1; GDSC2 -4.7849 14.0953 -10.827 52.2199
HCC2935 CTRP2 -3.7117 6.4843 -4.7261 59.9228
PC-14 GDSC1; GDSC2; CTRP2 -2.7969 2.2408 -2.8919 58.1009
PaCa-3 GDSC1; GDSC2 -1.7951 8.1798 -5.121 39.113
NCI-H1666 GDSC1; GDSC2; CTRP2 -1.4256 5.6821 -2.0119 49.715
COR-L105 GDSC1; GDSC2; CTRP2 -0.5952 4.168 -0.789 44.4962
NCI-H322M GDSC1; GDSC2 -0.275 8.8118 -4.0135 30.7967
RERF-LC-Sq1 GDSC1; GDSC2 -0.042 7.3151 -3.063 26.592
HCC95 CTRP2 0.1806 11.9429 -2.5609 43.4174
NCI-H1648 GDSC1; GDSC2 0.5012 4.3239 -1.094 14.658
Calu-3 GDSC1; GDSC2; CTRP2 0.7928 4.4629 0.6546 35.3446
EKVX GDSC1; GDSC2; CTRP2 0.8867 8.5429 -0.4204 37.7139
NCI-H187 GDSC1 1.0409 2.2085 -1.374 0.1411
NCI-H358 GDSC1; GDSC2; CTRP2 1.0955 4.8431 0.9176 33.4715
NCI-H1304 GDSC1 1.2869 9.6877 -4.5788 17.8026
LC-1/sq GDSC1; GDSC2 1.4105 11.5195 -3.9217 25.3288
NCI-H1435 GDSC1; GDSC2; CTRP2 1.4603 4.5431 1.3573 30.8138
NCI-H1781 GDSC1; GDSC2 1.5231 4.555 -0.3626 7.1884
NCI-H345 GDSC1; GDSC2 1.6238 2.955 0.4805 1.8501
NCI-H1568 GDSC1; GDSC2; CTRP2 1.6797 5.5753 1.4005 29.9481
SK-MES-1 GDSC1; GDSC2; CTRP2 1.6937 5.8595 1.3456 30.0843
CAL-12T GDSC1; GDSC2; CTRP2 1.82 10.6753 -0.3213 34.362
NCI-H322 CTRP2 1.8576 8.5815 0.5982 31.9321
NCI-H661 GDSC1; GDSC2; CTRP2 1.936 6.7127 1.3619 29.248
NCI-H1693 GDSC1; GDSC2; CTRP2 1.9533 5.9829 1.5963 28.4067
EMC-BAC-1 GDSC1; GDSC2 1.9576 12.2713 -3.8588 23.6518
A-427 GDSC1; GDSC2 2.0178 5.3889 -0.4151 6.3628
NCI-H1573 GDSC1; GDSC2; CTRP2 2.0789 5.9134 1.7518 27.4762
NCI-H1623 GDSC1; GDSC2 2.0792 8.5032 -1.8946 14.7112
EPLC-272H GDSC1; GDSC2; CTRP2 2.0973 10.78 -0.0838 32.9349
RERF-LC-KJ GDSC1; GDSC2 2.0983 7.7868 -1.5273 12.6784
NCI-H82 GDSC1; GDSC2 2.119 18.4398 -6.8058 31.0995
NCI-H1688 GDSC1; GDSC2 2.2162 4.0224 0.3416 1.6867
NCI-H1734 GDSC1; GDSC2; CTRP2 2.2231 4.3357 2.1877 25.5188
NCI-H1105 GDSC1; GDSC2 2.246 4.6537 0.0775 3.0481
NCI-H2461 GDSC1; GDSC2 2.3153 5.2444 -0.1519 4.2213
EMC-BAC-2 GDSC1; GDSC2 2.3329 5.0908 -0.0702 3.7263
COLO 668 GDSC1; GDSC2 2.3538 5.1479 -0.0837 3.7662
NCI-H2170 GDSC1; GDSC2; CTRP2 2.4235 5.5005 2.2269 24.742
DMS 79 GDSC1; GDSC2 2.4459 5.9459 -0.3969 5.3871
NCI-H2373 GDSC1; GDSC2 2.4489 4.9924 0.0429 2.9114
EBC-1 GDSC1; GDSC2; CTRP2 2.4657 3.3212 2.4657 23.7876
NCI-H513 GDSC1; GDSC2 2.4722 6.0186 -0.4142 5.437
NCI-H1963 GDSC1; GDSC2 2.5127 4.9806 0.0841 2.5962
NCI-H292 GDSC1; GDSC2; CTRP2 2.5402 9.5041 0.93 28.7709
LUDLU-1 CTRP2 2.5453 4.7246 2.4886 23.503
ABC-1 GDSC1; GDSC2 2.5513 5.8424 -0.2829 4.5435
NCI-H2081 GDSC1; GDSC2 2.5521 5.081 0.0617 2.6561
LXF 289 GDSC1; GDSC2; CTRP2 2.5745 4.0364 2.5673 23.0886
NCI-H64 GDSC1; GDSC2 2.6188 3.7149 0.6446 0.1907
NCI-H1341 GDSC1; GDSC2; CTRP2 2.6207 3.7617 2.6193 22.7621
DMS 454 CTRP2 2.6276 4.4547 2.6007 22.8536
NCI-H810 GDSC1; GDSC2; CTRP2 2.6319 3.3734 2.6319 22.6828
NCI-H524 GDSC1; GDSC2 2.6353 5.4258 -0.0444 3.0933
NCI-H2369 GDSC1; GDSC2 2.6675 3.8805 0.604 0.2629
DMS 53 GDSC1; GDSC2; CTRP2 2.695 4.3676 2.6765 22.3252
COR-L321 GDSC1; GDSC2 2.698 4.3831 0.4276 0.7952
NCI-H2405 GDSC1; GDSC2; CTRP2 2.7044 5.1852 2.5929 22.5805
DV-90 CTRP2 2.7173 4.9019 2.6496 22.3947
NCI-H1437 GDSC1; GDSC2 2.719 7.3608 -0.8872 7.6685
NCI-H1944 GDSC1; GDSC2; CTRP2 2.7326 4.4809 2.7082 22.0952
NCI-H2141 GDSC1; GDSC2; CTRP2 2.7497 5.0391 2.665 22.1869
NCI-H2135 GDSC1; GDSC2 2.7634 4.4898 0.4148 0.7915
Lu-135 GDSC1; GDSC2 2.7809 5.7666 -0.1137 3.2417
COR-L279 GDSC1; GDSC2 2.7903 4.2901 0.5025 0.4784
NCI-H2122 GDSC1; GDSC2; CTRP2 2.8167 4.7957 2.768 21.6182
NCI-H1836 GDSC1; GDSC2 2.8254 4.6794 0.368 0.9179
NCI-H1694 GDSC1; GDSC2; CTRP2 2.8278 4.0326 2.8247 21.3908
NCI-H2171 GDSC2 2.8336 4.2962 0.5178 0.4121
COR-L311 GDSC2 2.8379 4.8121 0.3209 1.0965
HOP-92 GDSC1; GDSC2; CTRP2 2.844 5.2436 2.7332 21.6504
COR-L88 GDSC1; GDSC2 2.856 13.9981 -4.0246 22.0415
Sq-1 CTRP2 2.8565 4.3698 2.8432 21.2828
NCI-H2110 GDSC1; GDSC2; CTRP2 2.86 8.3748 1.7401 25.1532
NCI-H596 GDSC1; GDSC2 2.8767 5.0206 0.2549 1.3306
NCI-H250 GDSC2 2.8876 4.6772 0.3963 0.768
IST-SL2 GDSC1; GDSC2 2.899 5.5343 0.0515 2.239
SW1271 GDSC1; GDSC2; CTRP2 2.8994 4.2048 2.8935 20.9243
NCI-H69 GDSC1; GDSC2; CTRP2 2.9187 4.488 2.9009 20.836
NCI-H522 GDSC2; CTRP2 2.9193 5.4424 2.7774 21.307
NCI-H290 GDSC1; GDSC2 2.9274 8.5794 -1.3288 9.7097
NCI-H720 GDSC1; GDSC2 2.9431 15.7132 -4.8067 24.3725
NCI-H2795 GDSC1; GDSC2 2.9618 6.0114 -0.1214 3.02
NCI-H2087 GDSC1; GDSC2; CTRP2 2.9646 6.019 2.6902 21.4265
COR-L303 GDSC2 2.99 4.5016 0.5043 0.3725
NCI-H2066 GDSC1; GDSC2 2.993 4.8553 0.3731 0.7711
HCC33 GDSC2 2.9988 4.6651 0.4476 0.5269
NCI-H146 GDSC1; GDSC2 2.9992 5.6008 0.0747 2.0073
NCI-H1975 GDSC1; GDSC2; CTRP2 3.0132 5.3707 2.893 20.5589
NCI-H1436 GDSC1; GDSC2 3.0308 4.5181 0.5142 0.3288
HCC1588 CTRP2 3.0353 7.1865 2.3905 22.3553
IST-SL1 GDSC1; GDSC2 3.0869 5.498 0.1604 1.5268
HOP-62 GDSC1; GDSC2; CTRP2 3.1131 4.7782 3.082 19.5887
NCI-H1876 GDSC1; GDSC2 3.1159 4.8212 0.437 0.4922
COR-L23 GDSC1; GDSC2 3.1243 4.4461 0.5743 0.1735
NCI-H1355 GDSC1; GDSC2; CTRP2 3.1329 6.8207 2.6256 21.1573
NCI-H211 GDSC1; GDSC2; CTRP2 3.1648 4.2387 3.1621 19.1498
NCI-H1838 GDSC1; GDSC2; CTRP2 3.1656 7.4597 2.4281 21.7907
NCI-H2804 GDSC1; GDSC2 3.1697 5.7215 0.1086 1.6672
NCI-H1993 GDSC1; GDSC2 3.1821 4.8911 0.4377 0.4567
NCI-H1092 GDSC1; GDSC2 3.1962 11.9992 -2.7942 16.4115
NCI-H1048 GDSC1; GDSC2 3.1984 4.7666 0.4891 0.3207
LB647-SCLC GDSC1; GDSC2 3.2367 15.7647 -4.6113 23.122
NCI-H510A GDSC1; GDSC2 3.2488 4.8336 0.4843 0.3123
NCI-H847 GDSC1; GDSC2 3.2588 4.5715 0.5791 0.1347
SBC-1 GDSC1; GDSC2 3.2632 5.0239 0.4211 0.4621
Lu-165 GDSC1; GDSC2 3.2657 4.5872 0.5762 0.1375
NCI-H2227 GDSC1; GDSC2 3.2842 5.1071 0.3989 0.5126
SK-LU-1 GDSC1; GDSC2; CTRP2 3.2936 4.8475 3.2653 18.3796
UMC-11 GDSC1; GDSC2 3.3295 5.1499 0.4012 0.4835
NCI-H2444 GDSC1; GDSC2; CTRP2 3.3627 5.1468 3.3051 18.0199
HCC366 GDSC1; GDSC2; CTRP2 3.3878 7.1688 2.7757 19.864
NCI-H1155 GDSC1; GDSC2; CTRP2 3.4247 4.3692 3.4227 17.4197
NCI-H1184 CTRP2 3.428 4.9704 3.395 17.5419
NCI-H1755 GDSC1; GDSC2; CTRP2 3.4286 5.8844 3.2318 18.07
NCI-H2722 GDSC1; GDSC2 3.4381 4.9627 0.5088 0.2036
LCLC-97TM1 GDSC1; GDSC2; CTRP2 3.4409 5.6325 3.304 17.776
NCI-H2818 GDSC1; GDSC2 3.4538 5.2991 0.3956 0.4404
NCI-H1770 GDSC1; GDSC2 3.4823 7.054 -0.2943 3.1873
NCI-H2228 GDSC1; GDSC2; CTRP2 3.4831 5.8579 3.2978 17.6672
NCI-H2810 GDSC1; GDSC2 3.484 6.211 0.0586 1.5728
NCI-H2106 CTRP2 3.4986 5.076 3.4584 17.0961
LK-2 GDSC1; GDSC2 3.5008 5.1412 0.4695 0.2575
Ms-1 GDSC1; GDSC2 3.5076 11.0591 -2.1244 12.6312
NCI-H3122 GDSC1; GDSC2 3.5143 5.5971 0.3101 0.6456
LC-2/ad GDSC1; GDSC2 3.5154 5.5319 0.3347 0.5738
NCI-H1373 CTRP2 3.5534 5.2549 3.4936 16.7984
Lu-99A GDSC1; GDSC2 3.559 5.673 0.3 0.6508
NCI-H1581 GDSC1; GDSC2; CTRP2 3.5682 5.0649 3.5332 16.577
HCC44 GDSC1; GDSC2; CTRP2 3.603 5.5176 3.5032 16.5691
SBC-3 GDSC1; GDSC2 3.6065 5.6305 0.3347 0.5284
CPC-N GDSC1; GDSC2 3.6097 6.1938 0.1226 1.2135
LC-1F CTRP2 3.6181 6.4797 3.266 17.4155
NCI-H209 GDSC1; GDSC2 3.621 10.252 -1.6666 10.1162
NCI-H2803 GDSC1; GDSC2 3.6362 10.0317 -1.5534 9.5058
NCI-H2023 GDSC1; GDSC2; CTRP2 3.6632 5.8049 3.507 16.3676
MOR/CPR CTRP2 3.6784 4.577 3.6759 15.7712
NCI-H2030 GDSC1; GDSC2; CTRP2 3.7043 10.5316 1.6423 23.1811
NCI-H1792 GDSC1; GDSC2; CTRP2 3.7089 8.1729 2.7118 19.2143
NCI-H748 GDSC2 3.7402 5.8599 0.3035 0.5496
Lu-99 CTRP2 3.7489 5.3068 3.6953 15.4747
IA-LM GDSC1; GDSC2; CTRP2 3.7603 6.2272 3.4995 16.0991
NCI-H835 GDSC1; GDSC2 3.7877 7.4292 -0.2961 2.8196
COLO 699 CTRP2 3.7967 5.6012 3.6967 15.3178
LC-1/sq-SF CTRP2 3.8289 6.8217 3.3772 16.3881
NCI-H2591 GDSC1; GDSC2 3.838 7.5353 -0.3154 2.8506
NCI-H1869 GDSC1; GDSC2; CTRP2 3.8449 11.0939 1.5142 23.2643
HCC2108 CTRP2 3.8553 5.3939 3.7964 14.7841
Lu-65 GDSC1; GDSC2; CTRP2 3.8587 6.6278 3.4776 15.8898
NCI-H446 GDSC1; GDSC2; CTRP2 3.8619 5.2136 3.8274 14.6234
RERF-LC-A1 CTRP2 3.8997 5.2473 3.8636 14.4105
HCC15 GDSC1; GDSC2; CTRP2 3.9067 5.7216 3.791 14.6071
Calu-6 GDSC1; GDSC2; CTRP2 3.9154 5.6835 3.8086 14.5179
NCI-H2291 GDSC1; GDSC2; CTRP2 3.923 7.8486 3.0722 17.2536
LCLC-103H GDSC1; GDSC2; CTRP2 3.9249 5.0124 3.9114 14.1335
NCI-H2731 GDSC1; GDSC2 3.9256 5.8786 0.3675 0.3247
SW1573 GDSC1; GDSC2 3.9392 6.3969 0.185 0.7802
NCI-H1793 GDSC1; GDSC2; CTRP2 3.9498 7.9763 3.0458 17.2839
COR-L32 GDSC2 3.9502 6.1192 0.2912 0.4867
NCI-H2595 GDSC1; GDSC2 3.9707 5.8948 0.3784 0.2897
NCI-H2347 GDSC1; GDSC2 3.9947 5.8199 0.413 0.2228
NCI-H226 GDSC1; GDSC2; CTRP2 4.0057 5.0751 3.9911 13.6002
NCI-H740 GDSC2 4.0254 6.4379 0.2046 0.6791
NCI-H2126 CTRP2 4.0529 9.4335 2.4981 19.1755
BEN GDSC1; GDSC2; CTRP2 4.1171 4.8322 4.1154 12.8163
HCC78 GDSC1; GDSC2; CTRP2 4.1612 5.3174 4.1326 12.6137
NCI-H1703 GDSC1; GDSC2; CTRP2 4.1654 5.8544 4.0424 12.9148
NCI-H526 GDSC1; GDSC2; CTRP2 4.1935 10.7498 2.0146 20.6011
A-549 GDSC1; GDSC2; CTRP2 4.1937 7.0114 3.6976 14.1082
DMS 114 GDSC1; GDSC2; CTRP2 4.2189 7.6516 3.4636 14.9425
Lu-139 GDSC1 4.2449 22.02 -8.4864 24.5611
SBC-5 GDSC1; GDSC2; CTRP2 4.2535 5.1856 4.2413 11.9449
SHP-77 GDSC1; GDSC2; CTRP2 4.2997 5.4967 4.2571 11.7416
NCI-H2869 GDSC1; GDSC2 4.3103 6.1146 0.4235 0.1445
NCI-H650 GDSC1; GDSC2; CTRP2 4.3257 6.2918 4.0957 12.2374
RERF-LC-Ad1 CTRP2 4.342 5.7782 4.2519 11.6521
NCI-H441 GDSC1; GDSC2; CTRP2 4.3675 10.4124 2.3431 18.9439
NCI-H1563 GDSC1; GDSC2; CTRP2 4.4237 9.1367 3.0029 16.2357
RERF-LC-MS GDSC1; GDSC2; CTRP2 4.45 6.7361 4.0764 11.9504
NCI-H841 GDSC1; GDSC2; CTRP2 4.4742 8.5614 3.32 14.8501
Lu-134-A GDSC1; GDSC2 4.4803 13.8151 -2.791 13.7721
NCI-H196 GDSC1; GDSC2; CTRP2 4.531 6.2872 4.3207 10.8043
NCI-H23 GDSC1; GDSC2; CTRP2 4.5525 6.5637 4.2498 11.0053
NCI-H2196 GDSC2; CTRP2 4.5572 5.6479 4.5099 10.0691
COR-L95 GDSC1; CTRP2 4.5622 5.6682 4.5119 10.0234
NCI-H2172 GDSC1; GDSC2; CTRP2 4.6936 7.0034 4.2307 10.6853
DMS 273 GDSC1; GDSC2; CTRP2 4.7047 6.45 4.4544 9.802
HCC1171 CTRP2 4.7165 11.6469 2.0719 19.1783
HARA [Human squamous cell lung carcinoma] GDSC1; GDSC2; CTRP2 4.7422 11.3141 2.2587 18.3762
NCI-H1395 CTRP2 4.7519 7.7267 3.979 11.5476
NCI-H1299 GDSC1; GDSC2; CTRP2 4.7612 7.1505 4.2403 10.4658
NCI-H647 GDSC1; GDSC2; CTRP2 4.7836 6.4781 4.5296 9.2938
NCI-H889 CTRP2 4.7882 9.5604 3.1545 14.7852
COR-L51 CTRP2 4.8865 7.7557 4.1017 10.7152
NCI-H2009 GDSC1; GDSC2; CTRP2 4.8934 8.7972 3.6212 12.6152
T3M-10 CTRP2 4.8955 5.8084 4.8462 7.8231
NCI-H1651 GDSC1; GDSC2; CTRP2 4.9144 8.2015 3.9233 11.34
NCI-H1650 GDSC1; GDSC2; CTRP2 4.9356 16.2996 -0.0342 25.463
HCC1438 CTRP2 4.9829 8.4478 3.874 11.4006
NCI-H727 GDSC1; GDSC2; CTRP2 5.0411 14.4161 0.9956 22.1519
ChaGo-K-1 GDSC1; GDSC2; CTRP2 5.1918 6.209 5.0643 6.12
VMRC-LCD GDSC1; GDSC2; CTRP2 5.2008 8.2976 4.1556 9.7105
NCI-H2029 GDSC1; GDSC2; CTRP2 5.2174 6.2476 5.0792 5.9902
NCI-H2342 GDSC1; GDSC2; CTRP2 5.253 8.4569 4.1285 9.7006
RERF-LC-Ad2 CTRP2 5.2586 7.0432 4.7994 6.978
Calu-1 CTRP2 5.2587 9.2548 3.7451 11.2914
NCI-H838 GDSC1; GDSC2; CTRP2 5.2674 6.2162 5.144 5.6042
HCC1195 CTRP2 5.2748 8.2549 4.2467 9.1855
NCI-H1915 GDSC1; GDSC2; CTRP2 5.277 10.7729 3.0137 14.2143
NCI-H2286 CTRP2 5.327 9.1506 3.8593 10.6672
NCI-H1339 CTRP2 5.4274 5.9194 5.4006 4.2023
NCI-H520 GDSC1; GDSC2; CTRP2 5.8377 8.865 4.4584 7.0603
KNS-62 GDSC1; GDSC2; CTRP2 5.9031 9.9914 3.952 9.0471
NCI-H460 GDSC1; GDSC2; CTRP2 6.0451 8.2784 4.928 4.6805
HCC1833 CTRP2 6.1494 14.8689 1.7194 17.3982
LOU-NH91 GDSC1; GDSC2; CTRP2 6.3398 21.9252 -1.6512 26.5761
HCC2279 CTRP2 7.2228 20.5654 -0.2589 21.5869
NCI-H2085 GDSC1; GDSC2; CTRP2 7.9774 14.8442 3.1327 8.8621
LK2 CTRP2 8.0955 21.5631 -0.0789 19.5914
Hs 888.Lu CTRP2 4.9315 6.4629 4.6945 8.2706
⏷ Show the Full List of 222 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1; GDSC2 3.57 5.8582 0.2349 0.8472
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 -0.9098 2.8274 -3.532 10.319
Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 4.7359 16.4879 -0.3043 26.6746
SNU-119 CTRP2 0.8183 6.73 0.14 36.7526
SNU-840 CTRP2 0.8564 9.2982 -0.748 38.5491
COV644 CTRP2 1.2361 10.0906 -0.6743 37.0898
JHOS-4 GDSC1; GDSC2 1.5922 4.5847 -0.326 6.7933
IGROV-1 GDSC1; GDSC2; CTRP2 1.7069 6.5426 1.1659 30.6273
RMG-I GDSC1; GDSC2; CTRP2 1.7705 9.3634 0.1884 33.2674
OVCAR-3 GDSC1; GDSC2 2.3018 4.4545 0.1991 2.3015
OC 314 GDSC1; GDSC2; CTRP2 2.3813 4.9136 2.2891 24.6605
OV7 CTRP2 2.4441 4.6545 2.3895 24.1699
Caov-4 GDSC1; GDSC2 2.5605 5.0644 0.0737 2.5814
COV434 CTRP2 2.6329 5.0272 2.5416 23.038
OVKATE GDSC1; GDSC2 2.6374 6.4113 -0.4932 5.58
MCAS CTRP2 2.9316 5.4487 2.7894 21.2261
OVTOKO GDSC1; GDSC2; CTRP2 2.9903 9.1324 1.5556 25.421
OVCAR-5 GDSC1; GDSC2; CTRP2 3.0123 5.9972 2.7481 21.0736
A2780 GDSC1; GDSC2; CTRP2 3.1367 5.3178 3.0359 19.6707
TYK-nu GDSC1; GDSC2; CTRP2 3.2856 4.7979 3.2611 18.42
JHOC-5 CTRP2 3.3586 9.8313 1.621 24.2258
OVK18 GDSC1; GDSC2; CTRP2 3.3764 4.6826 3.3631 17.7785
FU-OV-1 GDSC1; GDSC2; CTRP2 3.4156 8.7559 2.1575 22.0927
Caov-3 GDSC2; CTRP2 3.4996 6.2178 3.218 17.9446
SNU-8 CTRP2 3.5239 4.8504 3.5057 16.853
ES-2 GDSC1; GDSC2 3.5412 4.8335 0.5884 0.0777
OVSAHO CTRP2 3.5624 6.9944 3.0277 18.4648
ONCO-DG-1 CTRP2 3.6056 5.875 3.4272 16.8674
OAW28 GDSC1; GDSC2; CTRP2 3.7491 7.0595 3.204 17.2291
OVISE GDSC1; GDSC2; CTRP2 3.8355 4.4948 3.8351 14.684
ES2 CTRP2 3.9997 5.1371 3.9802 13.6875
Kuramochi GDSC1; GDSC2; CTRP2 4.0355 7.3516 3.3953 15.7031
SK-OV-3 GDSC1; GDSC2; CTRP2 4.0476 7.9488 3.159 16.5842
OVCAR-8 GDSC1; GDSC2; CTRP2 4.2871 6.9405 3.8245 13.3642
DOV13 GDSC1; GDSC2; CTRP2 4.3061 5.2279 4.293 11.598
HEY A8 CTRP2 4.4837 6.6212 4.155 11.5846
OAW42 GDSC1; GDSC2; CTRP2 4.6242 6.5379 4.3364 10.4753
OVCAR-4 GDSC1; GDSC2; CTRP2 4.7095 13.9083 0.9512 23.0444
COV362 CTRP2 4.9923 6.5385 4.7316 7.9578
OV56 GDSC1; GDSC2; CTRP2 5.2467 6.0359 5.1762 5.5481
JHOS-2 GDSC1; GDSC2; CTRP2 5.2729 7.9665 4.3834 8.6094
EFO-27 GDSC1; GDSC2; CTRP2 5.3271 10.8136 3.0385 14.0058
OV-90 GDSC1; GDSC2; CTRP2 5.3449 6.0815 5.2705 4.9105
TOV-21G GDSC1; GDSC2; CTRP2 5.3481 6.0508 5.2828 4.8563
EFO-21 GDSC1; GDSC2; CTRP2 5.6148 6.0784 5.5658 3.0278
TOV-112D GDSC1; GDSC2; CTRP2 6.5063 14.2368 2.3264 14.4423
JHOM-1 CTRP2 8.0997 9.281 5.6659 0.0775
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 7.7398 8.8544 5.6839 0.1175
TE 617.T CTRP2 -0.0368 3.3723 -0.0972 40.6842
BT-16 CTRP2 1.864 10.1328 -0.04 33.6144
Rh30 GDSC1; GDSC2 2.2794 4.2555 0.2743 1.9423
SW684 GDSC1; GDSC2 2.499 3.7908 0.57 0.4422
GCT GDSC1; GDSC2; CTRP2 2.5185 3.197 2.5185 23.4367
Rh18 GDSC1; CTRP2 2.5316 3.2547 2.5316 23.3493
Hs 633.T GDSC1; GDSC2 2.6751 4.3066 0.4474 0.7398
KYM-1 GDSC1; GDSC2; CTRP2 2.6831 3.9392 2.6799 22.3531
G-401 GDSC1; GDSC2; CTRP2 2.8817 4.2555 2.8738 21.0485
TE 441.T GDSC2; CTRP2 2.8841 4.5711 2.8594 21.1372
Rh41 GDSC1; GDSC2; CTRP2 2.9355 4.6932 2.9034 20.7725
EW-8 GDSC1; GDSC2 2.9599 4.8353 0.3665 0.8183
A-204 GDSC1; GDSC2; CTRP2 3.2767 5.5391 3.1454 18.8469
SW872 GDSC1; GDSC2 3.2781 4.8351 0.4947 0.279
MFH-ino GDSC1; GDSC2 3.8137 5.8786 0.3254 0.4592
STS-0421 GDSC1; GDSC2 4.036 6.5219 0.1778 0.7477
RKN GDSC1; GDSC2; CTRP2 4.1459 5.533 4.0864 12.8216
RD GDSC1; GDSC2; CTRP2 4.3651 6.7455 3.9818 12.5485
HT-1080 GDSC1; GDSC2; CTRP2 4.5955 5.3126 4.5879 9.656
G-402 GDSC1; GDSC2; CTRP2 4.6939 6.4604 4.4392 9.89
SK-LMS-1 GDSC1; GDSC2; CTRP2 4.7866 6.0869 4.6599 8.8039
Hs 729.T CTRP2 4.7914 6.1528 4.6459 8.8608
MES-SA GDSC1; GDSC2; CTRP2 5.0071 6.7265 4.6736 8.1203
SK-UT-1 GDSC1; GDSC2; CTRP2 5.3344 6.4429 5.1333 5.4537
VA-ES-BJ GDSC1; GDSC2 5.3898 15.6613 -3.075 13.3233
BT-12 CTRP2 6.9244 7.7807 5.7544 0.2582
SW982 GDSC1; GDSC2; CTRP2 8.0878 9.7048 5.5117 0.2954
Tm87-16 CTRP2 8.1925 10.5564 5.228 0.9128
TTC-709 CTRP2 9.5115 23.1199 0.1952 16.6092
⏷ Show the Full List of 30 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SYO-1 CTRP2 8.2729 20.6102 0.525 17.5402
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC1; GDSC2; CTRP2 2.0561 6.9438 1.4168 28.6846
NCI-H2452 GDSC1; GDSC2; CTRP2 3.1356 4.9146 3.0922 19.4808
NCI-H28 GDSC1; GDSC2; CTRP2 3.5904 5.1949 3.5414 16.4775
IST-Mes1 GDSC1; GDSC2; CTRP2 4.5288 6.6007 4.211 11.219
ACC-MESO-1 CTRP2 4.8511 6.1805 4.7026 8.4748
MPP 89 GDSC1; GDSC2; CTRP2 5.4331 6.2842 5.2992 4.5466
JL-1 CTRP2 7.909 15.462 2.7846 10.3264
NCI-H2052 GDSC1; GDSC2; CTRP2 9.1874 19.6137 1.6668 12.4404
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H660 GDSC2; CTRP2 2.6152 5.1302 2.5061 23.2175
22Rv1 GDSC1; GDSC2; CTRP2 4.0854 5.6909 3.9916 13.3434
PC-3 GDSC1; GDSC2 4.1639 6.6291 0.1894 0.6495
LNCaP clone FGC GDSC1; GDSC2; CTRP2 5.1721 6.3932 4.9786 6.4969
DU145 GDSC1; GDSC2; CTRP2 5.3506 8.9134 3.9974 10.0195
VCaP GDSC1; GDSC2; CTRP2 5.3761 6.1207 5.2929 4.7358
PaCa-3 CTRP2 5.663 6.1977 5.5781 2.8482
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 -1.8257 3.9803 -2.0817 52.1624
A-253 GDSC1; GDSC2; CTRP2 4.6546 8.7105 3.4294 13.9658
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1; GDSC2 2.3497 5.2316 -0.1247 4.0049
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCC-StC-K140 CTRP2 -3.455 9.4535 -5.4192 57.4454
SK-GT-2 GDSC1; GDSC2 -0.875 0.8558 -1.0087 19.4467
NUGC-4 GDSC1; GDSC2; CTRP2 -0.7544 4.3015 -0.9824 45.549
SNU-216 CTRP2 -0.5954 5.122 -0.9724 44.8553
NUGC-3 GDSC1; GDSC2; CTRP2 0.0448 5.8114 -0.441 41.0212
NCI-N87 GDSC1; GDSC2; CTRP2 0.3666 2.4232 0.3622 37.7547
KE-39 CTRP2 0.9981 7.4473 0.099 36.1971
GCIY GDSC1; GDSC2 1.2646 7.9834 -2.2738 18.854
HSC-39 GDSC1; GDSC2 2.2222 7.2973 -1.1973 10.5196
ECC10 GDSC1; GDSC2; CTRP2 2.4142 3.6661 2.4122 24.1364
IM95 GDSC1; GDSC2; CTRP2 2.433 6.7482 1.8907 25.8929
GSS CTRP2 2.5709 3.5773 2.5704 23.1426
RERF-GC-1B GDSC1; GDSC2 2.5791 6.0479 -0.3608 4.9345
MKN28 GDSC1; GDSC2 2.6142 5.9489 -0.2936 4.4934
SNU-16 GDSC1; GDSC2; CTRP2 2.6919 3.9717 2.6882 22.2964
MKN1 GDSC1; GDSC2 2.7346 7.0853 -0.747 6.8408
HGC-27 GDSC1; GDSC2; CTRP2 2.8282 4.5489 2.8028 21.4631
SCH GDSC1; GDSC2 2.8871 4.3446 0.5212 0.3749
TGBC11TKB GDSC1; GDSC2 2.9141 6.7587 -0.4837 5.0348
OCUM-1 GDSC1; GDSC2; CTRP2 3.0353 5.0382 2.9705 20.2205
SNU-620 CTRP2 3.288 4.204 3.2868 18.3674
TMK-1 GDSC1; GDSC2 3.3081 5.5217 0.252 0.9708
SNU-5 GDSC1; GDSC2; CTRP2 3.4182 4.3226 3.4168 17.4612
RF-48 GDSC1; GDSC2 3.4831 14.5451 -3.8311 19.9459
23132/87 GDSC1; GDSC2; CTRP2 3.614 4.7318 3.6055 16.1831
SNU-601 CTRP2 3.7381 5.6545 3.6223 15.7634
GSU CTRP2 3.8178 4.1888 3.8178 14.8337
SNU-1 GDSC1; GDSC2; CTRP2 3.9658 5.4983 3.8983 14.046
AGS GDSC1; GDSC2; CTRP2 3.9888 4.9508 3.9809 13.6901
KATO III GDSC1; GDSC2; CTRP2 4.1309 7.0832 3.6028 14.6451
MKN74 CTRP2 4.1743 7.463 3.4959 14.971
HuG1-N CTRP2 4.1813 6.669 3.8119 13.7427
Hs 746.T GDSC1; GDSC2; CTRP2 4.2378 5.8235 4.1284 12.386
ECC12 GDSC2; CTRP2 4.462 5.1834 4.4567 10.5597
SNU-668 CTRP2 5.1178 12.6162 1.9576 18.6906
LMSU CTRP2 5.1622 6.0588 5.0777 6.1733
MKN7 GDSC1; GDSC2; CTRP2 5.3098 11.6262 2.62 15.7105
SH-10-TC CTRP2 5.3491 5.9118 5.3173 4.7414
SNU-719 CTRP2 5.9916 15.2881 1.3785 18.9046
MKN45 GDSC1; GDSC2; CTRP2 7.3612 8.4634 5.6788 0.2332
Fu97 GDSC1; GDSC2; CTRP2 7.5528 17.7788 1.382 15.9635
SNG-M GDSC1; GDSC2; CTRP2 3.3785 5.4615 3.2709 18.0877
SNU-1077 CTRP2 3.9505 5.4364 3.8919 14.1492
SNU-685 CTRP2 4.9812 6.0341 4.8869 7.4125
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TT GDSC1; GDSC2; CTRP2 2.1336 6.0614 1.7717 27.2351
CAL-62 GDSC1; GDSC2 2.5141 4.2627 0.3911 1.1066
SW579 CTRP2 2.5347 2.9839 2.5347 23.3824
IHH-4 GDSC1; GDSC2 2.8927 4.1622 0.5887 0.2143
K5 GDSC1; GDSC2 2.8944 5.4602 0.0806 2.1039
ASH-3 GDSC1; GDSC2 3.0035 4.5991 0.474 0.4461
8305C GDSC1; GDSC2; CTRP2 3.236 4.5014 3.2273 18.6962
ML-1 [Human leukemia] GDSC1; GDSC2; CTRP2 3.3208 5.813 3.1319 18.7576
KMH-2 GDSC1; GDSC2 3.3605 5.2259 0.3856 0.5108
8505C GDSC1; GDSC2; CTRP2 3.4068 4.6249 3.3973 17.5637
WRO GDSC1; GDSC2 3.415 5.035 0.4752 0.2735
B-CPAP GDSC1; GDSC2; CTRP2 3.4419 4.0112 3.4419 17.2988
CGTH-W-1 GDSC1; GDSC2; CTRP2 4.0797 5.3698 4.0398 13.1941
HTC-C3 GDSC1; GDSC2 4.0848 11.0987 -1.7686 9.7671
BHT-101 GDSC1; GDSC2; CTRP2 4.2819 5.1763 4.2713 11.7508
FTC-238 CTRP2 5.2108 6.3131 5.0493 6.1345
TT2609-C02 GDSC1; GDSC2; CTRP2 5.5263 6.1915 5.4329 3.7779
FTC-133 GDSC1; GDSC2; CTRP2 5.5558 5.9907 5.5248 3.3549
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PCI-04B GDSC1; GDSC2 -3.672 0.9965 -4.0977 47.2912
NCI-H3118 GDSC1; GDSC2 -3.3204 2.9049 -4.3443 45.2029
BICR 78 GDSC1; GDSC2 -3.3168 4.486 -4.9705 45.8618
YD-10B CTRP2 -3.1663 2.9449 -3.362 59.8557
DOK GDSC1; GDSC2 -3.0467 3.9127 -4.4499 43.754
PCI-06A GDSC1; GDSC2 -2.761 7.1078 -5.5621 43.7669
SNU-1076 CTRP2 -1.8211 3.8996 -2.0633 52.1455
JHU-022 GDSC1; GDSC2 -1.6852 5.4288 -3.7165 35.3598
PCI-38 GDSC1 -1.4451 1.6318 -2.703 15.0559
SAT [Human HNSCC] GDSC1; GDSC2 -1.1825 8.5771 -4.732 35.9763
HO-1-u-1 GDSC1; GDSC2 -0.7369 4.4739 -2.3347 25.9622
Ca9-22 GDSC1; GDSC2 -0.7198 3.681 -1.9492 23.956
BHY GDSC1; GDSC2; CTRP2 -0.361 4.6523 -0.6211 43.1256
SNU-1214 CTRP2 -0.0897 5.6256 -0.5403 41.8701
BB30-HNC GDSC1; GDSC2 0.092 3.6238 -1.1285 16.2578
JHU-029 GDSC1; GDSC2 0.1587 5.6142 -2.041 21.1583
UPCI-SCC-090 GDSC1; GDSC2 0.2179 3.5982 -0.9972 15.0279
PCI-15A GDSC1; GDSC2 0.4309 4.0807 -1.037 14.545
SCC-25 GDSC1; GDSC2; CTRP2 0.4521 5.1334 0.1638 37.9957
BICR 56 CTRP2 0.5503 7.6673 -0.4617 39.1216
CAL-27 GDSC1; GDSC2; CTRP2 0.5866 8.7796 -0.8315 39.6103
JHU-011 GDSC1; GDSC2 0.6789 12.709 -5.1242 30.9505
PE/CA-PJ34 (clone C12) CTRP2 0.8492 5.8833 0.4179 35.9061
SCC-15 GDSC1; GDSC2 0.8628 6.6317 -1.931 18.2874
HSC-4 GDSC1; GDSC2; CTRP2 0.9394 9.6707 -0.811 38.3045
CAL-33 GDSC1; GDSC2; CTRP2 1.374 6.7654 0.7338 33.0741
HSC-2 GDSC1; GDSC2; CTRP2 1.5336 7.8865 0.5193 33.152
HSC-3 GDSC1; GDSC2; CTRP2 1.6441 5.9755 1.2609 30.5251
BB49-HNC GDSC1; GDSC2 1.6945 5.0912 -0.4996 7.6143
HO-1-N-1 GDSC1; GDSC2 1.9862 5.8446 -0.6577 7.8904
KON GDSC1; GDSC2 2.2616 6.8883 -0.9705 9.1187
OSC-19 GDSC1; GDSC2 2.4268 5.9881 -0.4289 5.6086
KOSC-2 GDSC1; GDSC2 2.4391 10.4368 -2.5793 17.2026
PE/CA-PJ49 CTRP2 2.6525 9.3826 1.0986 27.9686
OSC-20 GDSC1; GDSC2 2.8455 8.4558 -1.3247 9.8578
BICR 22 GDSC1; GDSC2; CTRP2 3.0422 8.9298 1.6966 24.7856
SAS GDSC1; GDSC2 3.0776 12.8392 -3.2901 18.7718
SCC-9 GDSC1; GDSC2; CTRP2 3.0955 7.1372 2.4732 21.8267
BICR 31 GDSC2; CTRP2 3.191 8.8259 1.8953 23.7166
SNU-899 CTRP2 3.2216 4.5016 3.2125 18.8365
BICR 10 GDSC1; GDSC2 3.2558 5.7337 0.1445 1.4308
YD-8 CTRP2 3.5341 6.0597 3.3006 17.5409
PCI-30 GDSC1; GDSC2 3.6849 13.443 -3.1509 16.8757
Detroit 562 GDSC1; GDSC2; CTRP2 4.0814 11.3869 1.6015 22.3644
PE/CA-PJ15 GDSC1; GDSC2; CTRP2 4.3707 10.7878 2.1658 19.6062
FaDu GDSC1; GDSC2; CTRP2 4.4401 16.0391 -0.3457 27.409
SNU-1041 CTRP2 4.4779 14.5992 0.4004 25.3169
SKN-3 GDSC1; GDSC2 4.5041 27.5077 -9.4589 31.0467
BICR 16 CTRP2 4.6534 9.6315 2.9914 15.7595
BICR 18 CTRP2 4.9149 6.4073 4.6965 8.3104
LB771-HNC GDSC1; GDSC2 5.2029 18.9796 -4.7741 19.7111
SNU-46 CTRP2 5.6609 12.3375 2.5728 15.1864
PE/CA-PJ41 (clone D2) CTRP2 6.1299 14.373 1.9511 16.5981
BICR 6 CTRP2 7.8853 16.5742 2.2238 12.4673
SNU-1066 CTRP2 8.9871 25.7511 -1.4769 21.7526
SCC-4 GDSC1; GDSC2; CTRP2 10.4157 27.9352 -1.5065 19.7248
⏷ Show the Full List of 56 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-BLC1 CTRP2 -3.2077 0.063 -3.2137 61.4537
SCaBER CTRP2 -0.2642 6.4506 -0.9555 43.3135
5637 GDSC1; GDSC2; CTRP2 0.8351 5.4545 0.5089 35.6232
253J-BV CTRP2 1.008 4.3391 0.9024 33.8971
VM-CUB-1 CTRP2 1.3415 6.3378 0.829 32.9725
BC-3C CTRP2 1.987 10.2676 0.0285 33.0567
CAL-29 GDSC1; GDSC2; CTRP2 2.1522 6.9037 1.5344 27.9882
HT-1376 GDSC1; GDSC2; CTRP2 2.4779 6.6129 1.9833 25.4298
SW780 GDSC1; GDSC2 2.5541 4.7528 0.2058 1.9205
253J CTRP2 2.7337 5.0788 2.6417 22.3693
RT-4 GDSC1; GDSC2; CTRP2 2.7507 6.1598 2.4177 23.0539
BFTC-905 GDSC1; GDSC2 2.8272 4.1995 0.5505 0.3264
JMSU-1 CTRP2 2.843 5.0673 2.7607 21.6079
KMBC-2 CTRP2 3.1261 10.6534 1.0125 26.8922
TCCSUP GDSC1; GDSC2; CTRP2 3.3778 4.3345 3.3759 17.7312
647V GDSC1; GDSC2; CTRP2 3.5812 6.7078 3.1497 17.914
RT-112 GDSC1; GDSC2; CTRP2 4.0473 5.5359 3.9797 13.5049
SW1710 GDSC1; GDSC2; CTRP2 4.3911 6.3909 4.1349 11.9008
UM-UC-1 CTRP2 4.4518 7.0433 3.9593 12.4207
639V GDSC1; GDSC2; CTRP2 4.4853 4.9467 4.485 10.3642
KU-19-19 GDSC1; GDSC2; CTRP2 4.7588 6.1949 4.5976 9.1143
UM-UC-3 GDSC1; GDSC2; CTRP2 5.0135 6.5973 4.7316 7.8802
HT-1197 GDSC1; GDSC2; CTRP2 5.101 6.0624 5.0099 6.5894
T24 GDSC1; GDSC2; CTRP2 5.1259 7.4345 4.4884 8.5408
J82 GDSC1; GDSC2; CTRP2 5.2344 7.5117 4.5607 7.9806
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OVMIU GDSC1; GDSC2 -1.4858 3.7085 -2.7386 30.978
OVCA420 GDSC1; GDSC2 -1.2958 3.0539 -2.2595 27.9573
CAL-39 GDSC1; GDSC2 -0.7027 3.6879 -1.9352 23.8133
BPH-1 GDSC1; GDSC2 -0.6734 3.3681 -1.76 22.7599
DSH1 GDSC1; GDSC2 0.6676 7.2089 -2.3857 21.2088
OMC-1 [Human cervical carcinoma] GDSC1; GDSC2 1.8878 6.1125 -0.8593 9.3293
ME-180 GDSC1; GDSC2 1.899 8.9181 -2.2371 16.9265
NCC-IT GDSC2 2.0104 3.974 0.2468 2.509
OVCA433 GDSC1; GDSC2 2.1075 7.9134 -1.5828 12.9625
C-33 A GDSC1; GDSC2 2.1253 5.817 -0.5475 6.9224
SKG-IIIa GDSC1; GDSC2 2.2386 5.9822 -0.5498 6.6949
C-4-I GDSC1; GDSC2 2.3335 5.4218 -0.223 4.5962
LB831-BLC GDSC1; GDSC2 2.3718 4.4397 0.244 1.9698
JHOS-3 GDSC1; GDSC2 2.3735 5.3021 -0.1427 4.0648
SW756 GDSC1; GDSC2 2.3939 4.5248 0.2189 2.0671
Ca Ski GDSC1; GDSC2 2.4152 7.7529 -1.2821 10.5586
NEC8 GDSC1; GDSC2 2.4199 4.2127 0.3658 1.3191
UWB1.289 GDSC1; GDSC2 2.4621 8.3542 -1.5413 11.8905
SW954 GDSC1; GDSC2 2.4754 8.5977 -1.6504 12.452
SiHa GDSC1; GDSC2 2.4832 3.5992 0.6344 0.2668
DoTc2 4510 GDSC1; GDSC2 2.5499 6.4993 -0.5902 6.3016
KGN GDSC1; GDSC2 2.577 5.4599 -0.0932 3.4466
OV17R GDSC1; GDSC2 2.6507 4.8969 0.1944 1.855
HEY GDSC1; GDSC2 2.7036 5.4514 -0.0175 2.8501
HT-3 GDSC1; GDSC2 2.7542 6.8737 -0.6354 6.1701
MS751 GDSC1; GDSC2 2.7601 6.5252 -0.4699 5.2261
SW962 GDSC1; GDSC2 2.8162 7.5412 -0.9091 7.5994
SKN GDSC1; GDSC2 2.8177 7.1143 -0.7076 6.4594
JEG-3 GDSC1; GDSC2 2.9268 4.8625 0.3412 0.9373
TC-YIK GDSC1; GDSC2 2.9387 5.8308 -0.0552 2.7153
PEO1 GDSC1; GDSC2 3.0067 5.0692 0.2956 1.0463
NT2-D1 GDSC1; GDSC2 3.051 7.5598 -0.769 6.3733
SiSo GDSC1; GDSC2 3.244 5.272 0.3205 0.7778
PA-1 GDSC1; GDSC2 3.2455 5.2291 0.3375 0.721
JAR GDSC1; GDSC2 3.3237 5.1079 0.4142 0.4516
HEC-1 GDSC1; GDSC2 3.627 5.0992 0.5289 0.1316
PWR-1E GDSC1; GDSC2 3.7309 5.9967 0.2494 0.7052
ACC-OV7 GDSC1; GDSC2 7.2837 26.3443 -6.8952 21.9279
HeLa GDSC1; GDSC2; CTRP2 7.6893 16.7809 1.9777 13.6543
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Gefitinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Decreased metabolism of Gefitinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [22]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Gefitinib and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [23]
Armodafinil DMGB035 Minor Increased metabolism of Gefitinib caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [24]
LEE011 DMMX75K Moderate Decreased metabolism of Gefitinib caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [22]
Epirubicin DMPDW6T Moderate Increased risk of hepatotoxicity by the combination of Gefitinib and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [25]
Coadministration of a Drug Treating the Disease Different from Gefitinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Gefitinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [25]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Gefitinib and Thioguanine. Acute myeloid leukaemia [2A60] [26]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Gefitinib caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [22]
Arn-509 DMT81LZ Moderate Increased metabolism of Gefitinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [22]
Mitotane DMU1GX0 Moderate Increased metabolism of Gefitinib caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [22]
Donepezil DMIYG7Z Minor Decreased metabolism of Gefitinib caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [27]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Gefitinib caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [22]
Nifedipine DMSVOZT Moderate Decreased metabolism of Gefitinib caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [22]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Gefitinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [28]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Gefitinib caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [22]
Voriconazole DMAOL2S Moderate Decreased metabolism of Gefitinib caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [22]
Posaconazole DMUL5EW Moderate Decreased metabolism of Gefitinib caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [22]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Gefitinib caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [22]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Gefitinib caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Gefitinib caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Gefitinib caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Gefitinib caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Rabeprazole DMMZXIW Moderate Decreased absorption of Gefitinib due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [29]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Gefitinib caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Gefitinib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [30]
Talazoparib DM1KS78 Moderate Decreased clearance of Gefitinib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [31]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Gefitinib caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [22]
Tucatinib DMBESUA Moderate Decreased metabolism of Gefitinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [22]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Gefitinib caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [22]
Mifepristone DMGZQEF Moderate Decreased metabolism of Gefitinib caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [25]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Gefitinib caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [22]
Aminoglutethimide DMWFHMZ Moderate Increased metabolism of Gefitinib caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [22]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Gefitinib caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [22]
MK-8228 DMOB58Q Moderate Decreased metabolism of Gefitinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [22]
Aprepitant DM053KT Moderate Decreased metabolism of Gefitinib caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [32]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Gefitinib caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [22]
Duloxetine DM9BI7M Moderate Decreased metabolism of Gefitinib caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [33]
Griseofulvin DMK54YG Moderate Increased metabolism of Gefitinib caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [22]
Primidone DM0WX6I Moderate Increased metabolism of Gefitinib caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Felbamate DM1V5ZS Moderate Increased metabolism of Gefitinib caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Gefitinib caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Cenobamate DM8KLU9 Moderate Increased metabolism of Gefitinib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Gefitinib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Phenobarbital DMXZOCG Moderate Increased metabolism of Gefitinib caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Carbamazepine DMZOLBI Moderate Increased metabolism of Gefitinib caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [22]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Gefitinib and Cannabidiol. Epileptic encephalopathy [8A62] [23]
Timolol DM3NXRU Moderate Decreased metabolism of Gefitinib caused by Timolol mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [34]
Tazemetostat DMWP1BH Moderate Increased metabolism of Gefitinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [22]
Tolterodine DMSHPW8 Minor Decreased metabolism of Gefitinib caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [35]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Gefitinib caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [36]
Itraconazole DMCR1MV Moderate Decreased metabolism of Gefitinib caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [22]
Miconazole DMPMYE8 Moderate Decreased metabolism of Gefitinib caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [22]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Gefitinib caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [22]
Dexlansoprazole DM1DBV5 Moderate Decreased absorption of Gefitinib due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [29]
Omeprazole DM471KJ Moderate Decreased absorption of Gefitinib due to altered gastric pH caused by Omeprazole. Gastro-oesophageal reflux disease [DA22] [29]
Nizatidine DMGFV3Z Moderate Decreased absorption of Gefitinib due to altered gastric pH caused by Nizatidine. Gastro-oesophageal reflux disease [DA22] [29]
Cimetidine DMH61ZB Moderate Decreased absorption of Gefitinib due to altered gastric pH caused by Cimetidine. Gastro-oesophageal reflux disease [DA22] [29]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Gefitinib caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [22]
Boceprevir DMBSHMF Moderate Decreased metabolism of Gefitinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [22]
Telaprevir DMMRV29 Moderate Decreased metabolism of Gefitinib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [22]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Gefitinib caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [22]
Rifampin DMA8J1G Moderate Increased metabolism of Gefitinib caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [22]
Rifapentine DMCHV4I Moderate Increased metabolism of Gefitinib caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [22]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Gefitinib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [37]
Delavirdine DM3NF5G Moderate Decreased metabolism of Gefitinib caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Gefitinib caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Gefitinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Efavirenz DMC0GSJ Moderate Increased metabolism of Gefitinib caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Saquinavir DMG814N Moderate Decreased metabolism of Gefitinib caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Etravirine DMGV8QU Moderate Increased metabolism of Gefitinib caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Gefitinib caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Darunavir DMN3GCH Moderate Decreased metabolism of Gefitinib caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Atazanavir DMSYRBX Moderate Decreased metabolism of Gefitinib caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Ritonavir DMU764S Moderate Decreased metabolism of Gefitinib caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Gefitinib and Mipomersen. Hyper-lipoproteinaemia [5C80] [38]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Gefitinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [39]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Gefitinib and BMS-201038. Hyper-lipoproteinaemia [5C80] [40]
Verapamil DMA7PEW Moderate Decreased metabolism of Gefitinib caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [22]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Gefitinib caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [22]
Conivaptan DM1V329 Moderate Decreased metabolism of Gefitinib caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [22]
Givosiran DM5PFIJ Moderate Decreased metabolism of Gefitinib caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [41]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Gefitinib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [22]
Amobarbital DM0GQ8N Moderate Increased metabolism of Gefitinib caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [22]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Gefitinib and Methotrexate. Leukaemia [2A60-2B33] [23]
Crizotinib DM4F29C Moderate Decreased metabolism of Gefitinib caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [22]
Brigatinib DM7W94S Moderate Increased metabolism of Gefitinib caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [42]
Ceritinib DMB920Z Moderate Decreased metabolism of Gefitinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [22]
PF-06463922 DMKM7EW Moderate Increased metabolism of Gefitinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [22]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Gefitinib caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [43]
Selpercatinib DMZR15V Moderate Decreased metabolism of Gefitinib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [22]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Gefitinib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [44]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Gefitinib and Idelalisib. Mature B-cell leukaemia [2A82] [45]
IPI-145 DMWA24P Moderate Decreased metabolism of Gefitinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [22]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Gefitinib and Clofarabine. Mature B-cell lymphoma [2A85] [46]
Arry-162 DM1P6FR Moderate Decreased clearance of Gefitinib due to the transporter inhibition by Arry-162. Melanoma [2C30] [25]
Vemurafenib DM62UG5 Moderate Increased metabolism of Gefitinib caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [22]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Gefitinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [22]
Danazol DML8KTN Moderate Decreased metabolism of Gefitinib caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [22]
Ubrogepant DM749I3 Moderate Decreased clearance of Gefitinib due to the transporter inhibition by Ubrogepant. Migraine [8A80] [47]
Rimegepant DMHOAUG Moderate Decreased clearance of Gefitinib due to the transporter inhibition by Rimegepant. Migraine [8A80] [48]
Exjade DMHPRWG Moderate Decreased metabolism of Gefitinib caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [49]
Rifabutin DM1YBHK Moderate Increased metabolism of Gefitinib caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [22]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Gefitinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [22]
Nilotinib DM7HXWT Moderate Decreased metabolism of Gefitinib caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [22]
Imatinib DM7RJXL Moderate Decreased metabolism of Gefitinib caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [22]
Dasatinib DMJV2EK Moderate Decreased metabolism of Gefitinib caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [22]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Gefitinib and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [50]
Modafinil DMYILBE Minor Increased metabolism of Gefitinib caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [24]
Netupitant DMEKAYI Moderate Decreased metabolism of Gefitinib caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [22]
Entrectinib DMMPTLH Moderate Decreased metabolism of Gefitinib caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [22]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Gefitinib caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [22]
Codeine DMJX6ZG Moderate Decreased metabolism of Gefitinib caused by Codeine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [51]
Abametapir DM2RX0I Moderate Decreased metabolism of Gefitinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [52]
Ranitidine DM0GUSX Moderate Decreased absorption of Gefitinib due to altered gastric pH caused by Ranitidine. Peptic ulcer [DA61] [29]
Esomeprazole DM7BN0X Moderate Decreased absorption of Gefitinib due to altered gastric pH caused by Esomeprazole. Peptic ulcer [DA61] [29]
Famotidine DMRL3AB Moderate Decreased absorption of Gefitinib due to altered gastric pH caused by Famotidine. Peptic ulcer [DA61] [29]
Lefamulin DME6G97 Moderate Decreased metabolism of Gefitinib caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [53]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Gefitinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [22]
Enzalutamide DMGL19D Moderate Increased metabolism of Gefitinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [22]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Gefitinib caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [22]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Gefitinib and Verteporfin. Psoriasis [EA90] [23]
Bosentan DMIOGBU Moderate Increased metabolism of Gefitinib caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [22]
Riociguat DMXBLMP Moderate Decreased metabolism of Gefitinib caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [39]
Dexamethasone DMMWZET Moderate Increased metabolism of Gefitinib caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [22]
Nafcillin DMN9RPO Moderate Increased metabolism of Gefitinib caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [22]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Gefitinib and Leflunomide. Rheumatoid arthritis [FA20] [39]
Thioridazine DM35M8J Major Decreased metabolism of Gefitinib caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [54]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Gefitinib caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [55]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Gefitinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [22]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Gefitinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [23]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Gefitinib and Naltrexone. Substance abuse [6C40] [56]
Fostamatinib DM6AUHV Moderate Decreased clearance of Gefitinib due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [57]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Gefitinib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [58]
Elagolix DMB2C0E Moderate Increased metabolism of Gefitinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [22]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Gefitinib caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [22]
⏷ Show the Full List of 130 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 300 E00651 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Gefitinib 250 mg tablet 250 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Gefitinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941).
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
8 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
9 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
10 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
11 Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009 Aug;68(2):226-37.
12 Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
13 Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005;44(10):1067-81.
14 Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
15 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
16 Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 2004 Dec 15;13(24):3029-43. doi: 10.1093/hmg/ddh331. Epub 2004 Oct 20.
17 Aurora-A promotes gefitinib resistance via a NF-B signaling pathway in p53 knockdown lung cancer cells. Biochem Biophys Res Commun. 2011 Feb 11;405(2):168-72. doi: 10.1016/j.bbrc.2011.01.001. Epub 2011 Jan 7.
18 EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
19 Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
20 BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer. Med Oncol. 2011 Jun;28(2):572-7. doi: 10.1007/s12032-010-9470-y. Epub 2010 Mar 17.
21 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
22 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
23 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
24 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
25 Cerner Multum, Inc. "Australian Product Information.".
26 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
27 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
28 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
29 Product Information. Iressa (gefitinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
30 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
31 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
32 Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
33 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
34 Edeki TI, He HB, Wood AJJ "Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction." JAMA 274 (1995): 1611-3. [PMID: 7474246]
35 Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
36 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
37 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
38 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
39 Canadian Pharmacists Association.
40 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
41 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
42 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
43 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
45 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
46 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
47 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
48 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
49 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
50 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
51 Caraco Y, Sheller J, Wood AJJ "Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects." J Pharmacol Exp Ther 290 (1999): 413-22. [PMID: 10381807]
52 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
53 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
54 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
55 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
56 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
57 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
58 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".